AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesInformation ScienceNamed GroupsHealth CareGeographicals
Bronchopulmonary DysplasiaAspergillosis, Allergic BronchopulmonaryInfant, PrematureInfant, NewbornInfant, Very Low Birth WeightHyperoxiaInfant, Premature, DiseasesRespiratory Distress Syndrome, NewbornInfant, Extremely Low Birth WeightGestational AgeBronchopulmonary SequestrationLungUreaplasma InfectionsRespiration, ArtificialIntensive Care Units, NeonatalOxygen Inhalation TherapyFibrous Dysplasia of BoneInfant, Extremely PrematureUreaplasma urealyticumChorioamnionitisPulmonary SurfactantsRespiratory AspirationPulmonary AlveoliIntensive Care, NeonatalEctodermal DysplasiaPapioAnimals, NewbornLung InjuryBone Diseases, DevelopmentalUreaplasmaLung DiseasesLeukomalacia, PeriventricularInfant, Low Birth WeightDevelopmental DisabilitiesAmbroxolTracheaRetinopathy of PrematurityAspergillus fumigatusSucking BehaviorApneaConsensus Development Conferences, NIH as TopicDuctus Arteriosus, PatentApgar ScorePremature BirthHyaline Membrane DiseaseBirth WeightTransducers, PressureMaximal Expiratory Flow RatePregnancyFunctional Residual CapacityUterine Cervical DysplasiaDexamethasoneBronchial DiseasesFibromuscular DysplasiaPneumocytesGastrointestinal ContentsIntermittent Positive-Pressure VentilationContinuous Positive Airway PressureSuctionPsychomotor DisordersAdministration, InhalationBronchoalveolar Lavage FluidVentilator WeaningOsteochondrodysplasiasPortugalRetrospective StudiesFibrous Dysplasia, MonostoticDisease Models, AnimalFatty AlcoholsRespiratory Function TestsFibrous Dysplasia, PolyostoticFetusLung Diseases, FungalOxygenEnterocolitis, NecrotizingProspective StudiesHip Dysplasia, CanineBronchiectasisCleidocranial DysplasiaRetinal DysplasiaInfant, Newborn, DiseasesCerebral PalsyRisk FactorsFollow-Up StudiesBronchial NeoplasmsAdrenal Cortex HormonesHip Dislocation, Congenital
Bronchopulmonary Dysplasia: A chronic lung disease developed after OXYGEN INHALATION THERAPY or mechanical ventilation (VENTILATION, MECHANICAL) usually occurring in certain premature infants (INFANT, PREMATURE) or newborn infants with respiratory distress syndrome (RESPIRATORY DISTRESS SYNDROME, NEWBORN). Histologically, it is characterized by the unusual abnormalities of the bronchioles, such as METAPLASIA, decrease in alveolar number, and formation of CYSTS.Aspergillosis, Allergic Bronchopulmonary: Hypersensitivity reaction (ALLERGIC REACTION) to fungus ASPERGILLUS in an individual with long-standing BRONCHIAL ASTHMA. It is characterized by pulmonary infiltrates, EOSINOPHILIA, elevated serum IMMUNOGLOBULIN E, and skin reactivity to Aspergillus antigen.Infant, Premature: A human infant born before 37 weeks of GESTATION.Infant, Newborn: An infant during the first month after birth.Infant, Very Low Birth Weight: An infant whose weight at birth is less than 1500 grams (3.3 lbs), regardless of gestational age.Hyperoxia: An abnormal increase in the amount of oxygen in the tissues and organs.Infant, Premature, DiseasesRespiratory Distress Syndrome, Newborn: A condition of the newborn marked by DYSPNEA with CYANOSIS, heralded by such prodromal signs as dilatation of the alae nasi, expiratory grunt, and retraction of the suprasternal notch or costal margins, mostly frequently occurring in premature infants, children of diabetic mothers, and infants delivered by cesarean section, and sometimes with no apparent predisposing cause.Infant, Extremely Low Birth Weight: An infant whose weight at birth is less than 1000 grams (2.2 lbs), regardless of GESTATIONAL AGE.Gestational Age: The age of the conceptus, beginning from the time of FERTILIZATION. In clinical obstetrics, the gestational age is often estimated as the time from the last day of the last MENSTRUATION which is about 2 weeks before OVULATION and fertilization.Bronchopulmonary Sequestration: A developmental anomaly in which a mass of nonfunctioning lung tissue lacks normal connection with the tracheobroncheal tree and receives an anomalous blood supply originating from the descending thoracic or abdominal aorta. The mass may be extralobar, i.e., completely separated from normally connected lung, or intralobar, i.e., partly surrounded by normal lung.Lung: Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood.Ureaplasma Infections: Infections with bacteria of the genus UREAPLASMA.Respiration, Artificial: Any method of artificial breathing that employs mechanical or non-mechanical means to force the air into and out of the lungs. Artificial respiration or ventilation is used in individuals who have stopped breathing or have RESPIRATORY INSUFFICIENCY to increase their intake of oxygen (O2) and excretion of carbon dioxide (CO2).Intensive Care Units, Neonatal: Hospital units providing continuing surveillance and care to acutely ill newborn infants.Oxygen Inhalation Therapy: Inhalation of oxygen aimed at restoring toward normal any pathophysiologic alterations of gas exchange in the cardiopulmonary system, as by the use of a respirator, nasal catheter, tent, chamber, or mask. (From Dorland, 27th ed & Stedman, 25th ed)Fibrous Dysplasia of Bone: A disease of bone marked by thinning of the cortex by fibrous tissue containing bony spicules, producing pain, disability, and gradually increasing deformity. Only one bone may be involved (FIBROUS DYSPLASIA, MONOSTOTIC) or several (FIBROUS DYSPLASIA, POLYOSTOTIC).Infant, Extremely Premature: A human infant born before 28 weeks of GESTATION.Ureaplasma urealyticum: A species of gram-negative bacteria found in the human genitourinary tract (UROGENITAL SYSTEM), oropharynx, and anal canal. Serovars 1, 3, 6, and 14 have been reclassed into a separate species UREAPLASMA parvum.Chorioamnionitis: INFLAMMATION of the placental membranes (CHORION; AMNION) and connected tissues such as fetal BLOOD VESSELS and UMBILICAL CORD. It is often associated with intrauterine ascending infections during PREGNANCY.Pulmonary Surfactants: Substances and drugs that lower the SURFACE TENSION of the mucoid layer lining the PULMONARY ALVEOLI.Respiratory Aspiration: Inhaling liquid or solids, such as stomach contents, into the RESPIRATORY TRACT. When this causes severe lung damage, it is called ASPIRATION PNEUMONIA.Pulmonary Alveoli: Small polyhedral outpouchings along the walls of the alveolar sacs, alveolar ducts and terminal bronchioles through the walls of which gas exchange between alveolar air and pulmonary capillary blood takes place.Intensive Care, Neonatal: Continuous care and monitoring of newborn infants with life-threatening conditions, in any setting.Ectodermal Dysplasia: A group of hereditary disorders involving tissues and structures derived from the embryonic ectoderm. They are characterized by the presence of abnormalities at birth and involvement of both the epidermis and skin appendages. They are generally nonprogressive and diffuse. Various forms exist, including anhidrotic and hidrotic dysplasias, FOCAL DERMAL HYPOPLASIA, and aplasia cutis congenita.Papio: A genus of the subfamily CERCOPITHECINAE, family CERCOPITHECIDAE, consisting of five named species: PAPIO URSINUS (chacma baboon), PAPIO CYNOCEPHALUS (yellow baboon), PAPIO PAPIO (western baboon), PAPIO ANUBIS (or olive baboon), and PAPIO HAMADRYAS (hamadryas baboon). Members of the Papio genus inhabit open woodland, savannahs, grassland, and rocky hill country. Some authors consider MANDRILLUS a subgenus of Papio.Animals, Newborn: Refers to animals in the period of time just after birth.Lung Injury: Damage to any compartment of the lung caused by physical, chemical, or biological agents which characteristically elicit inflammatory reaction. These inflammatory reactions can either be acute and dominated by NEUTROPHILS, or chronic and dominated by LYMPHOCYTES and MACROPHAGES.Bone Diseases, DevelopmentalUreaplasma: A genus of gram-negative, nonmotile bacteria which are common parasitic inhabitants of the urogenital tracts of humans, cattle, dogs, and monkeys.Lung Diseases: Pathological processes involving any part of the LUNG.Leukomalacia, Periventricular: Degeneration of white matter adjacent to the CEREBRAL VENTRICLES following cerebral hypoxia or BRAIN ISCHEMIA in neonates. The condition primarily affects white matter in the perfusion zone between superficial and deep branches of the MIDDLE CEREBRAL ARTERY. Clinical manifestations include VISION DISORDERS; CEREBRAL PALSY; PARAPLEGIA; SEIZURES; and cognitive disorders. (From Adams et al., Principles of Neurology, 6th ed, p1021; Joynt, Clinical Neurology, 1997, Ch4, pp30-1)Infant, Low Birth Weight: An infant having a birth weight of 2500 gm. (5.5 lb.) or less but INFANT, VERY LOW BIRTH WEIGHT is available for infants having a birth weight of 1500 grams (3.3 lb.) or less.Developmental Disabilities: Disorders in which there is a delay in development based on that expected for a given age level or stage of development. These impairments or disabilities originate before age 18, may be expected to continue indefinitely, and constitute a substantial impairment. Biological and nonbiological factors are involved in these disorders. (From American Psychiatric Glossary, 6th ed)Ambroxol: A metabolite of BROMHEXINE that stimulates mucociliary action and clears the air passages in the respiratory tract. It is usually administered as the hydrochloride.Trachea: The cartilaginous and membranous tube descending from the larynx and branching into the right and left main bronchi.Retinopathy of Prematurity: A bilateral retinopathy occurring in premature infants treated with excessively high concentrations of oxygen, characterized by vascular dilatation, proliferation, and tortuosity, edema, and retinal detachment, with ultimate conversion of the retina into a fibrous mass that can be seen as a dense retrolental membrane. Usually growth of the eye is arrested and may result in microophthalmia, and blindness may occur. (Dorland, 27th ed)Aspergillus fumigatus: A species of imperfect fungi from which the antibiotic fumigatin is obtained. Its spores may cause respiratory infection in birds and mammals.Sucking Behavior: Any suction exerted by the mouth; response of the mammalian infant to draw milk from the breast. Includes sucking on inanimate objects. Not to be used for thumb sucking, which is indexed under fingersucking.Apnea: A transient absence of spontaneous respiration.Consensus Development Conferences, NIH as Topic: Articles on conferences sponsored by NIH presenting summary statements representing the majority agreement of physicians, scientists, and other professionals convening for the purpose of reaching a consensus on a subject of interest. This heading is used for NIH consensus conferences as a means of scientific communication. In indexing it is viewed as a type of review article and as a tag for any article appearing in any publication of the NIH Office of Medical Applications of Research (OMAR).Ductus Arteriosus, Patent: A congenital heart defect characterized by the persistent opening of fetal DUCTUS ARTERIOSUS that connects the PULMONARY ARTERY to the descending aorta (AORTA, DESCENDING) allowing unoxygenated blood to bypass the lung and flow to the PLACENTA. Normally, the ductus is closed shortly after birth.Apgar Score: A method, developed by Dr. Virginia Apgar, to evaluate a newborn's adjustment to extrauterine life. Five items - heart rate, respiratory effort, muscle tone, reflex irritability, and color - are evaluated 60 seconds after birth and again five minutes later on a scale from 0-2, 0 being the lowest, 2 being normal. The five numbers are added for the Apgar score. A score of 0-3 represents severe distress, 4-7 indicates moderate distress, and a score of 7-10 predicts an absence of difficulty in adjusting to extrauterine life.Premature Birth: CHILDBIRTH before 37 weeks of PREGNANCY (259 days from the first day of the mother's last menstrual period, or 245 days after FERTILIZATION).Hyaline Membrane Disease: A respiratory distress syndrome in newborn infants, usually premature infants with insufficient PULMONARY SURFACTANTS. The disease is characterized by the formation of a HYALINE-like membrane lining the terminal respiratory airspaces (PULMONARY ALVEOLI) and subsequent collapse of the lung (PULMONARY ATELECTASIS).Birth Weight: The mass or quantity of heaviness of an individual at BIRTH. It is expressed by units of pounds or kilograms.Transducers, Pressure: Transducers that are activated by pressure changes, e.g., blood pressure.Maximal Expiratory Flow Rate: The airflow rate measured during the first liter expired after the first 200 ml have been exhausted during a FORCED VITAL CAPACITY determination. Common abbreviations are MEFR, FEF 200-1200, and FEF 0.2-1.2.Pregnancy: The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.Functional Residual Capacity: The volume of air remaining in the LUNGS at the end of a normal, quiet expiration. It is the sum of the RESIDUAL VOLUME and the EXPIRATORY RESERVE VOLUME. Common abbreviation is FRC.Uterine Cervical Dysplasia: Abnormal development of immature squamous EPITHELIAL CELLS of the UTERINE CERVIX, a term used to describe premalignant cytological changes in the cervical EPITHELIUM. These atypical cells do not penetrate the epithelial BASEMENT MEMBRANE.Dexamethasone: An anti-inflammatory 9-fluoro-glucocorticoid.Bronchial DiseasesFibromuscular Dysplasia: An idiopathic, segmental, nonatheromatous disease of the musculature of arterial walls, leading to STENOSIS of small and medium-sized arteries. There is true proliferation of SMOOTH MUSCLE CELLS and fibrous tissue. Fibromuscular dysplasia lesions are smooth stenosis and occur most often in the renal and carotid arteries. They may also occur in other peripheral arteries of the extremity.Pneumocytes: Epithelial cells that line the PULMONARY ALVEOLI.Gastrointestinal Contents: The contents included in all or any segment of the GASTROINTESTINAL TRACT.Intermittent Positive-Pressure Ventilation: Application of positive pressure to the inspiratory phase when the patient has an artificial airway in place and is connected to a ventilator.Continuous Positive Airway Pressure: A technique of respiratory therapy, in either spontaneously breathing or mechanically ventilated patients, in which airway pressure is maintained above atmospheric pressure throughout the respiratory cycle by pressurization of the ventilatory circuit. (On-Line Medical Dictionary [Internet]. Newcastle upon Tyne(UK): The University Dept. of Medical Oncology: The CancerWEB Project; c1997-2003 [cited 2003 Apr 17]. Available from: http://cancerweb.ncl.ac.uk/omd/)Suction: The removal of secretions, gas or fluid from hollow or tubular organs or cavities by means of a tube and a device that acts on negative pressure.Psychomotor Disorders: Abnormalities of motor function that are associated with organic and non-organic cognitive disorders.Administration, Inhalation: The administration of drugs by the respiratory route. It includes insufflation into the respiratory tract.Bronchoalveolar Lavage Fluid: Washing liquid obtained from irrigation of the lung, including the BRONCHI and the PULMONARY ALVEOLI. It is generally used to assess biochemical, inflammatory, or infection status of the lung.Ventilator Weaning: Techniques for effecting the transition of the respiratory-failure patient from mechanical ventilation to spontaneous ventilation, while meeting the criteria that tidal volume be above a given threshold (greater than 5 ml/kg), respiratory frequency be below a given count (less than 30 breaths/min), and oxygen partial pressure be above a given threshold (PaO2 greater than 50mm Hg). Weaning studies focus on finding methods to monitor and predict the outcome of mechanical ventilator weaning as well as finding ventilatory support techniques which will facilitate successful weaning. Present methods include intermittent mandatory ventilation, intermittent positive pressure ventilation, and mandatory minute volume ventilation.Osteochondrodysplasias: Abnormal development of cartilage and bone.PortugalRetrospective Studies: Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.Fibrous Dysplasia, Monostotic: FIBROUS DYSPLASIA OF BONE involving only one bone.Disease Models, Animal: Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.Fatty Alcohols: Usually high-molecular-weight, straight-chain primary alcohols, but can also range from as few as 4 carbons, derived from natural fats and oils, including lauryl, stearyl, oleyl, and linoleyl alcohols. They are used in pharmaceuticals, cosmetics, detergents, plastics, and lube oils and in textile manufacture. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed)Respiratory Function Tests: Measurement of the various processes involved in the act of respiration: inspiration, expiration, oxygen and carbon dioxide exchange, lung volume and compliance, etc.Fibrous Dysplasia, Polyostotic: FIBROUS DYSPLASIA OF BONE affecting several bones. When melanotic pigmentation (CAFE-AU-LAIT SPOTS) and multiple endocrine hyperfunction are additionally associated it is referred to as Albright syndrome.Fetus: The unborn young of a viviparous mammal, in the postembryonic period, after the major structures have been outlined. In humans, the unborn young from the end of the eighth week after CONCEPTION until BIRTH, as distinguished from the earlier EMBRYO, MAMMALIAN.Lung Diseases, Fungal: Pulmonary diseases caused by fungal infections, usually through hematogenous spread.Oxygen: An element with atomic symbol O, atomic number 8, and atomic weight [15.99903; 15.99977]. It is the most abundant element on earth and essential for respiration.Enterocolitis, Necrotizing: ENTEROCOLITIS with extensive ulceration (ULCER) and NECROSIS. It is observed primarily in LOW BIRTH WEIGHT INFANT.Prospective Studies: Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.Hip Dysplasia, Canine: A hereditary disease of the hip joints in dogs. Signs of the disease may be evident any time after 4 weeks of age.Bronchiectasis: Persistent abnormal dilatation of the bronchi.Cleidocranial Dysplasia: Autosomal dominant syndrome in which there is delayed closing of the CRANIAL FONTANELLES; complete or partial absence of the collarbones (CLAVICLES); wide PUBIC SYMPHYSIS; short middle phalanges of the fifth fingers; and dental and vertebral anomalies.Retinal Dysplasia: Congenital, often bilateral, retinal abnormality characterized by the arrangement of outer nuclear retinal cells in a palisading or radiating pattern surrounding a central ocular space. This disorder is sometimes hereditary.Infant, Newborn, Diseases: Diseases of newborn infants present at birth (congenital) or developing within the first month of birth. It does not include hereditary diseases not manifesting at birth or within the first 30 days of life nor does it include inborn errors of metabolism. Both HEREDITARY DISEASES and METABOLISM, INBORN ERRORS are available as general concepts.Cerebral Palsy: A heterogeneous group of nonprogressive motor disorders caused by chronic brain injuries that originate in the prenatal period, perinatal period, or first few years of life. The four major subtypes are spastic, athetoid, ataxic, and mixed cerebral palsy, with spastic forms being the most common. The motor disorder may range from difficulties with fine motor control to severe spasticity (see MUSCLE SPASTICITY) in all limbs. Spastic diplegia (Little disease) is the most common subtype, and is characterized by spasticity that is more prominent in the legs than in the arms. Pathologically, this condition may be associated with LEUKOMALACIA, PERIVENTRICULAR. (From Dev Med Child Neurol 1998 Aug;40(8):520-7)Risk Factors: An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.Follow-Up Studies: Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.Bronchial Neoplasms: Tumors or cancer of the BRONCHI.Adrenal Cortex HormonesHip Dislocation, Congenital: Congenital dislocation of the hip generally includes subluxation of the femoral head, acetabular dysplasia, and complete dislocation of the femoral head from the true acetabulum. This condition occurs in approximately 1 in 1000 live births and is more common in females than in males.

Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia. (1/452)

BACKGROUND: The safety and efficacy of inhaled glucocorticoid therapy for asthma stimulated its use in infants to prevent bronchopulmonary dysplasia. We tested the hypothesis that early therapy with inhaled glucocorticoids would decrease the frequency of bronchopulmonary dysplasia in premature infants. METHODS: We conducted a randomized, multicenter trial of inhaled beclomethasone or placebo in 253 infants, 3 to 14 days old, born before 33 weeks of gestation and weighing 1250 g or less at birth, who required ventilation therapy. Beclomethasone was delivered in a decreasing dosage, from 40 to 5 microg per kilogram of body weight per day, for four weeks. The primary outcome measure was bronchopulmonary dysplasia at 28 days of age. Secondary outcomes included bronchopulmonary dysplasia at 36 weeks of postmenstrual age, the need for systemic glucocorticoid therapy, the need for bronchodilator therapy, the duration of respiratory support, and death. RESULTS: One hundred twenty-three infants received beclomethasone, and 130 received placebo. The frequency of bronchopulmonary dysplasia was similar in the two groups: 43 percent in the beclomethasone group and 45 percent in the placebo group at 28 days of age, and 18 percent in the beclomethasone group and 20 percent in the placebo group at 36 weeks of postmenstrual age. At 28 days of age, fewer infants in the beclomethasone group than in the placebo group were receiving systemic glucocorticoid therapy (relative risk, 0.6; 95 percent confidence interval, 0.4 to 1.0) and mechanical ventilation (relative risk, 0.8; 95 percent confidence interval, 0.6 to 1.0). CONCLUSIONS: Early beclomethasone therapy did not prevent bronchopulmonary dysplasia but was associated with lower rates of use of systemic glucocorticoid therapy and mechanical ventilation.  (+info)

Effect of early ambroxol treatment on lung functions in mechanically ventilated preterm newborns who subsequently developed a bronchopulmonary dysplasia (BPD). (2/452)

In a randomized trial in 102 preterm newborns with respiratory distress syndrome (RDS) it has been shown that early Ambroxol treatment (30 mg kg(-1) over the first 5 days) significantly reduces the incidence of RDS-associated complications [bronchopulmonary dysplasia (BPD), intraventricular haemorrhage, post-natal acquired pneumonia]. The aim of the present analysis was to investigate the effect of Ambroxol treatment on lung function in newborns who developed BPD. Respiratory function testing (RFT) was performed immediately after extubation and at day 28. Tidal volume (VT) and respiratory frequency (f) were measured during tidal breathing using the deadspace free flow-through technique. The lung mechanic parameter VT/maxPes was determined by measuring the maximal oesophageal pressure changes, maxPes, with a catheter tip pressure transducer. In the placebo group 36/50 infants were extubated within the first 28 days of life and 13/36 (36%) developed BPD. In the Ambroxol group 44/52 were extubated and 9/44 (20%) developed BPD. After extubation, RFT showed (i) no statistically significant difference in the ventilatory parameters of either treatment group, (ii) improved (P<0.05) lung mechanics (VT/maxPes) in Ambroxol group compared to controls (94+/-27 ml kPa(-1) vs. 8.1+/-2.6 ml kPa(-1)) and (iii) no statistically significant difference in lung function between infants with and without BPD. At day 28 we found (i) no effect of early Ambroxol treatment on lung functions, (ii) significantly (P < 0.05) higher f (58.5+/-11.7 min(-1) vs. 49.7+/-10.1 min(-1)) and significantly (P<0.01) lower V(T) (9.6+/-1.9 ml vs. 12.3+/-2.7 ml) and V(T)/maxPes (8.9+/-2.6 ml kPa(-1)] vs. 12.0+/-2.9 ml kPa(-1)) in infants with BPD compared to infants without and (iii) these differences are not influenced by early Ambroxol treatment. If the process of BPD development is induced, early Ambroxol treatment has no influence on impaired lung function at day 28.  (+info)

Use of corticosteroids and the outcome of infants with bronchopulmonary dysplasia. (3/452)

Ventilator-dependent premature infants are often treated with dexamethasone. Several trials showed that steroids while improve pulmonary compliance and facilitate extubation, some treated infants may have adverse effects, such as alterations of growth curves. We conducted this retrospective study to evaluate the effects of steroids on mechanical ventilation, oxygen therapy, hospital length stay and mortality, in ventilator-dependent infants with bronchopulmonary dysplasia (BPD) (defined as the need of oxygen supplementation at 28 days of life). Twenty-six newborns with BPD were evaluated during 9 - 42 days postpartum (mean = 31 days) and were divided into two groups: Group I - 14 newborns that did not receive dexamethasone, and Group II - 12 newborns that received dexamethasone at 14 - 21 days of life. Dexamethasone was given at a dose of 0.25 mg per kilogram of body weight twice daily intravenously for 3 days, after which the dose was tapered. RESULTS: There were no statistically significant differences in the mean length of mechanical ventilation (Group I - 37 days, Group II - 35 days); oxygen supplementation (Group I - 16 days, Group II - 29 days); hospital stay (Group I - 72 days, Group II - 113 days); mortality (Group I - 35.7%, Group II - 41.6%). At birth, Group II was lighter (BW: Group I - 1154 grams +/- 302, Group II - 791 grams +/- 165; p < 0.05) and smaller (height: Group I - 37.22 cm +/- 3.3, Group II - 33.5 +/- 2.4; p< 0.05) than Group I. At 40 weeks, there were no statistically significant differences between groups in relation to anthropometric measurements. CONCLUSIONS: The use of corticosteroids in bronchopulmonary dysplasic infants may influence the somatic growth during its use. However, after its suspension, a recovery seems to occur, suggesting that its influence could be transitory.  (+info)

Cytokine response during hyperoxia: sequential production of pulmonary tumor necrosis factor and interleukin-6 in neonatal rats. (4/452)

BACKGROUND: Exposure of newborn animals to high concentrations of oxygen leads to diffuse alveolar damage similar to that seen in bronchopulmonary dysplasia in human infants. Therefore, neonatal rats are a suitable practical model of hyperoxic lung damage in human infants. OBJECTIVE: To determine the involvement of tumor necrosis factor-alpha and interleukin-6 in lung injury in neonatal rats exposed to 100% O2 concentration. METHODS: A randomized controlled study was designed in which litters of term Sprague-Dawley rat pups were assigned to experimental or control groups. The pups in the experimental group were placed in 100% O2 from birth for 9 days, while the control pups were placed in room air. Twelve to 15 pups from each group were sacrificed on day 1, 3, 6, 9 and 13 after birth for bronchoalveolar lavage collection and lung histologic study. The bronchoalveolar lavage fluid was assayed for TNF alpha and IL-6. RESULTS: Newborn rats exposed to 100% O2 for the first 9 days of life showed severe pulmonary edema and hypercellularity on days 1 and 3, which then improved to nearly complete resolution on days 6 and 9. Pulmonary TNF alpha was produced early on O2 exposure (day 3) and pulmonary IL-6 later (days 6 and 9). CONCLUSIONS: Hyperoxia induces sequential production of pulmonary TNF alpha and IL-6, which corresponds to the severity of the pathological findings and the known inflammatory and anti-inflammatory role of these cytokines.  (+info)

Birth weight <1501 g and respiratory health at age 14. (5/452)

AIMS: To determine the respiratory health in adolescence of children of birth weight <1501 g, and to compare the results with normal birthweight controls. METHODS: Prospective cohort study of children born in the Royal Women's Hospital, Melbourne. Two cohorts of preterm children (86 consecutive survivors 500-999 g birth weight, and 124 consecutive survivors 1000-1500 g birth weight) and a control group of 60 randomly selected children >2499 g birth weight were studied. Children were assessed at 14 years of age. A paediatrician determined the clinical respiratory status. Lung function was measured according to standard guidelines. RESULTS: Of 180 preterm children seen at age 14, 42 (23%) had bronchopulmonary dysplasia (BPD) in the newborn period. Readmission to hospital for respiratory ill health was infrequent in all groups and the rates of asthma were similar (15% in the 500-999 g birth weight group, 21% in the 1000-1500 g birth weight group, 21% in controls; 19% BPD, 18% no BPD). Overall, lung function was mostly within the normal range for all cohorts; few children had lung function abnormalities in clinically significant ranges. However, the preterm children had significantly lower values for variables reflecting flow. Lung function in children of 500-999 g birth weight was similar to children of 1000-1500 g birth weight. Preterm children with BPD had significantly lower values for variables reflecting flow than children without BPD. CONCLUSIONS: The respiratory health of children of birth weight <1501 g at 14 years of age is comparable to that of term controls.  (+info)

Chronic pulmonary insufficiency in children and its effects on growth and development. (6/452)

Conditions leading to chronic pulmonary insufficiency can affect infants and children. These can lead to growth failure and delayed development. Among the most common and severe of these are bronchopulmonary dysplasia (BPD) and cystic fibrosis. In addition to the respiratory consequences of these diseases, there is ample evidence that they lead to decreased growth as a result of decreased energy intake and increased energy expenditure. Furthermore, there is evidence that infants with BPD may also have delayed development, independent of the effects of their prematurity. Enhancing the long-term outlook for these conditions may therefore require consideration of both improved pulmonary management and aggressive nutritional management to limit growth failure and potentially enhance developmental outcome. Specific micronutrient supplementation, such as antioxidant therapy, may also enhance pulmonary and nutritional status.  (+info)

Special nutritional needs of infants for prevention of and recovery from bronchopulmonary dysplasia. (7/452)

Extremely low birth weight infants who develop severe respiratory disease may have special nutrient requirements imposed by a combination of enhanced utilization of nutrients or the need for epithelial cell repair resulting from the disease process, as well as to support catch-up growth. Inositol, free fatty acids, vitamin E and vitamin A are proposed as nutrients for which infants at risk of chronic pulmonary insufficiency may have special requirements. Of these nutrients, only for vitamin A does suggestive evidence exist that high doses when given intramuscularly may reduce the incidence of death or chronic lung disease. Exogenous steroid therapy (dexamethasone), which is often used to improve pulmonary compliance in ventilated premature infants, may compromise vitamin A status and induce restricted somatic and bone mineral growth. Supplemental nutrition by means of enriched infant formulas has provided benefits in growth and bone mass accretion to infants recovering from bronchopulmonary dysplasia up to 3-mo corrected age. This growth advantage was not sustained over the subsequent 9 mo, suggesting that prolonged nutritional support is required until catch-up growth is complete. Further studies are required to delineate the needs for specific nutrients such as antioxidant vitamins and minerals or vitamin A that may play a role in preventing severe chronic lung disease in premature infants. As well, the role of supplemental nutrition (beyond the requirements of term infants) to support catch-up growth and maintenance during the critical stages of early development requires further investigation before evidence-based nutrient recommendations can be developed for this special population of infants.  (+info)

Is there a role for antioxidant therapy in bronchopulmonary dysplasia? (8/452)

Bronchopulmonary dysplasia (BPD) is a chronic lung disease first described in 1967 as a complication of therapy for premature infants with hyaline membrane disease, and treatment with high concentrations of oxygen was thought to be a major contributor to its development. Thus, interventions to enhance lung antioxidants to prevent the development of BPD were considered appropriate therapeutic strategies. In the last decades, advances in the acute care of premature infants has reduced the reliance on therapy with high concentrations of supplemental oxygen. However, the incidence of BPD has not changed significantly. The changing clinical context in which BPD develops begs the question of whether oxidation is important in the development of BPD and, therefore, whether designing interventions enhancing lung antioxidants is still warranted. This review presents evidence that premature infants that will develop BPD have qualitative and quantitative differences in oxidation of lipids and proteins when compared to infants that do not develop BPD. Such differences in oxidation patterns are the most obvious in the first few days of life. The emerging evidence thus supports the concept that the lung injury process leading to the development of BPD occurs within hours to days of delivery and that oxidation is a major contributor to this pathological process. Unfortunately, early attempts at delivery of antioxidants to the lung have not been successful, perhaps because of an inability to deliver antioxidants in a timely manner to the areas in the lung in which deleterious oxidations are occurring. Further research is necessary to determine both the nature and the location of the oxidative events that lead to the development of early lung injury, so that more appropriate and specific antioxidant interventions can be designed.  (+info)

Erratum: Serial Changes of Serum Endostatin and Angiopoietin-1 Levels in Preterm Infants with Severe Bronchopulmonary Dysplasia...Erratum: Serial Changes of Serum Endostatin and Angiopoietin-1 Levels in Preterm Infants with Severe Bronchopulmonary Dysplasia...
Erratum: Serial Changes of Serum Endostatin and Angiopoietin-1 Levels in Preterm Infants with Severe Bronchopulmonary Dysplasia and Subsequent Pulmonary Artery Hypertension
Bronchopulmonary Dysplasia Treatment Market Research Study for the Period 2017-2027 - Find Market ResearchBronchopulmonary Dysplasia Treatment Market Research Study for the Period 2017-2027 - Find Market Research
The global bronchopulmonary dysplasia treatment market is classified on the basis of drug class, therapy type end user, and geography. Based on drug type, the global bronchopulmonary dysplasia treatment market is segmented into the following: Bronchodilators, Diuretics, Antibiotics, Steroids, Immunomodulators, Surfactant Homeostasis; Based on therapy type, the global bronchopulmonary dysplasia treatment market is segmented into the following: Nitric Oxide Therapy, Protein replacement therapy, Stem Cell Therapy, Supplemental Oxygen; Based on end user, the global bronchopulmonary dysplasia treatment market is segmented into the following: Hospitals, Nursing Homes, Critical Care Centers. Companies are focusing on the development of novel treatment option for bronchopulmonary dysplasia for the faster action and quick relief than the conventional dosage forms. For instance, Airway Therapeutics, LLC developed AT-100, a recombinant form of human surfactant protein, for maintaining healthy lung function ...
Impact of a Physiologic Definition on Bronchopulmonary Dysplasia Rates | American Academy of PediatricsImpact of a Physiologic Definition on Bronchopulmonary Dysplasia Rates | American Academy of Pediatrics
The physiologic definition of BPD standardized the definition of BPD among centers and led to a reduction in the overall rate of BPD from 35% to 25%. Variation in rates of BPD among centers was reduced modestly, but significant variation among centers remained even when using the physiologic definition.. The clinical definition was assigned at 36 weeks and 0 days postmenstrual age, whereas the physiologic definition was assigned between 35 and 37 weeks postmenstrual age. The wider window of time allowed infants who were steadily weaning from oxygen to reach room air in the window and also ensured that infants were not studied during an acute deterioration. This wider window resulted in more infants reaching room air and thus being assigned the outcome "no BPD." Thus, the number assigned the clinical definition of BPD is greater than the sum of those on positive pressure support, oxygen, and failed physiologic challenge, as shown in Fig 1. The difference is clinically relevant, because the ...
Best Practices in Severe BPD Treatment - Pediatrics NationwideBest Practices in Severe BPD Treatment - Pediatrics Nationwide
Infants with severe bronchopulmonary dysplasia (BPD) have high risks of late morbidities and mortality, but the best ways to manage these vulnerable patients are still debated. In fact, its not always clear how to define "severe BPD".. The Bronchopulmonary Dysplasia Collaborative, a group of institutions led by Nationwide Childrens Hospital, has recently published a review to guide neonatologists - and to help the multidisciplinary teams that are crucial for a patients ongoing care.. "One of the focuses of neonatology has been on the prevention of BPD," says Leif Nelin, MD, chief of the Division of Neonatology at Nationwide Childrens and senior author of The Journal of Pediatrics review. "Thats very important. When the disease occurs, however, patients are often taken care of as if they have an acute disease, when they actually have a chronic one. And once the neonatal intensive care unit phase is over, care can ultimately fall to a pulmonologist, a critical care specialist, a cardiologist ...
Bronchopulmonary Dysplasia. BPD information. Patient | PatientBronchopulmonary Dysplasia. BPD information. Patient | Patient
Is known as chronic lung disease (CLD) of prematurity. BPD Bronchopulmonary dysplasia (BPD) is a chronic lung disease. Read about Bronchopulmonary Dysplasia.
Airway administration of corticosteroids for prevention of bronchopulmonary dysplasia in premature infants: a meta-analysis...Airway administration of corticosteroids for prevention of bronchopulmonary dysplasia in premature infants: a meta-analysis...
Uncertainly prevails with regard to the use of inhalation or instillation steroids to prevent bronchopulmonary dysplasia in preterm infants. The meta-analysis with sequential analysis was designed to evaluate the efficacy and safety of airway administration (inhalation or instillation) of corticosteroids for preventing bronchopulmonary dysplasia (BPD) in premature infants. We searched MEDLINE, EMBASE, CINAHL, and Cochrane CENTRAL from their inceptions to February 2017. All published randomized controlled trials (RCTs) evaluating the effect of airway administration of corticosteroids (AACs) vs placebo or systemic corticosteroid in prematurity were included. All meta-analyses were performed using Review Manager 5.3. Twenty five RCTs retrieved (n = 3249) were eligible for further analysis. Meta-analysis and trial sequential analysis corrected the 95% confidence intervals estimated a lower risk of the primary outcome of BPD (relative risk 0.71, adjusted 95% confidence interval 0.57-0.87) and death or BPD
Normal pulmonary vascular resistance and left ventricular hypertrophy in young infants with bronchopulmonary dysplasia : An...Normal pulmonary vascular resistance and left ventricular hypertrophy in young infants with bronchopulmonary dysplasia : An...
TY - JOUR. T1 - Normal pulmonary vascular resistance and left ventricular hypertrophy in young infants with bronchopulmonary dysplasia. T2 - An echocardiographic and pathologic study. AU - Malnick, G.. AU - Pickoff, A. S.. AU - Ferrer, P. L.. AU - Peyser, J.. AU - Bancalari, Eduardo. AU - Gelband, H.. PY - 1980/12/24. Y1 - 1980/12/24. N2 - To evaluate the cardiac anatomy and functional hemodynamics in young infants with chronic lung disease, nine patients, aged 2 to 7 months, with a clinical diagnosis of bronchopulmonary dysplasia (BPD) underwent echocardiographic examination. All infants required supplemental O2 (mean FIO2 35%) to maintain adequate systemic oxygenation (Pao2 greater than 50 mm Hg). None of the infants had evidence of a patent ductus arteriosus at the time of examination. Echocardiographic measurements of left and right ventricular systolic time intervals revealed normal systolic time interval ratios suggesting normal left ventricular systolic function as well as normal ...
Pulmonary and Renal Responses to Furosemide in Infants With Stage III-IV Bronchopulmonary Dysplasia<...Pulmonary and Renal Responses to Furosemide in Infants With Stage III-IV Bronchopulmonary Dysplasia<...
TY - JOUR. T1 - Pulmonary and Renal Responses to Furosemide in Infants With Stage III-IV Bronchopulmonary Dysplasia. AU - Patel, Hemendra. AU - Yeh, Tsu Fuh. AU - Jain, Renu. AU - Pildes, Rosita. PY - 1985/1/1. Y1 - 1985/1/1. N2 - Pulmonary and renal responses to furosemide were evaluated in ten infants with stage III-IV bronchopulmonary dysplasia. Furosemide was given intravenously for two doses, 1 and 2 mg/kg, at approximately 24-hour intervals. The following indices were evaluated in series before and after entry Into study: clinical respiratory distress syndrome score; blood pH; partial pressure of arterial carbon dioxide; alveolar-arterial oxygen gradient; urine output; glomerular filtration rate; fractional excretion of filtered sodium, chloride, potassium, and calcium; osmolar clearance; water clearance; and concentrations of serum electrolytes and calcium. A significant decrease in the respiratory distress syndrome score and in the partial pressure of arterial carbon dioxide was seen ...
Bronchopulmonary Dysplasia Global Clinical Trials Review, H1, 2013 | Jul 23, 2013 - ReleaseWireBronchopulmonary Dysplasia Global Clinical Trials Review, H1, 2013 | Jul 23, 2013 - ReleaseWire
Press Release issued Jul 23, 2013: Reportstack, provider of premium market research reports announces the addition of Bronchopulmonary Dysplasia Global Clinical Trials Review, H1, 2013 market report to its offering Bronchopulmonary Dysplasia Global Clinical Trials Review, H1, 2013
Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia | MetaValidation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia | Meta
A number of definitions of bronchopulmonary dysplasia (BPD), or chronic lung disease, have been used. A June 2000 National Institute of Child Health and Human Development/National Heart, Lung, and Blood Institute Workshop proposed a severity-based definition of BPD for infants ,32 weeks gestational age (GA). Mild BPD was defined as a need for supplemental oxygen (O2) for , or =28 days but not at 36 weeks postmenstrual age (PMA) or discharge, moderate BPD as O2 for , or =28 days plus treatment with ,30% O2 at 36 weeks PMA, and severe BPD as O2 for , or =28 days plus , or =30% O2 and/or positive pressure at 36 weeks PMA. The objective of this study was to determine the predictive validity of the severity-based, consensus definition of BPD. Data from 4866 infants (birth weight , or =1000 g, GA ,32 weeks, alive at 36 weeks PMA) who were entered into the National Institute of Child Health and Human Development Neonatal Research Network Very Low Birth weight (VLBW) Infant Registry between January ...
Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia - Full Text View -...Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia - Full Text View -...
HYPOTHESIS:. Early prophylactic inhalation of Budesonide reduces the absolute risk of developing bronchopulmonary dysplasia (BPD) or death in preterm infants born ,28 weeks gestational age (GA) by 10%.. PRIMARY OBJECTIVE:. To determine whether inhalation of Budesonide within 12 hours of life improves survival without BPD at 36 weeks GA in infants born between 23 and 27 weeks GA.. SECONDARY OBJECTIVES:. To determine whether prophylactic inhalation of Budesonide affects neurodevelopment at a corrected age of 18-22 months in preterm infants; to determine whether inhalation of corticosteroids is associated with adverse treatment effects, alters mortality at 36 weeks GA, BPD incidence at 36 weeks GA, and the duration of positive pressure respiratory support or supplemental oxygen.. RATIONALE:. Pre- and postnatal exposure of the developing lung to inflammation is central to the development of BPD and the pulmonary inflammatory response in preterms at risk of developing BPD is established very early in ...
Adrenomedullin regulated by miRNA-574-3p protects premature infants with bronchopulmonary dysplasia | Bioscience Reports |...Adrenomedullin regulated by miRNA-574-3p protects premature infants with bronchopulmonary dysplasia | Bioscience Reports |...
Bronchopulmonary dysplasia (BPD) is the most common chronic lung disease (CLD) in premature infants. This study was designed to elucidate the regulation of miRNA-547-3p on adrenomedullin (ADM) during the pathogenesis of BPD. We used Agilent Human 4x44K Gene Expression Microarrays v2 and miRCURY LNA™ microRNA Array to identify the differently expressed miRNA and its potential target genes, and certified them again by luciferase reporter gene analysis. We only retained target genes that met the following two conditions: first, coexisting in two databases, and second, expressing differences, and then identifying target genes by luciferase reporter gene analysis. Thus, we selected miRNA-574-3p and its target gene ADM for further research. We used real-time q-PCR to determine the expression of miRNA-574-3p and its target gene ADM in premature infants with BPD. We used microarray expression to analyze BPD samples and non-BPD samples and found that there were 516 differently expressed probes between ...
Incidence of and risk factors for neonatal morbidity after active perinatal care: extremely preterm infants study in Sweden ...Incidence of and risk factors for neonatal morbidity after active perinatal care: extremely preterm infants study in Sweden ...
Aims: The aim of this study was to determine the incidence of neonatal morbidity in extremely preterm infants and to identify associated risk factors. Methods: Population based study of infants born before 27 gestational weeks and admitted for neonatal intensive care in Sweden during 2004-2007. Results: Of 638 admitted infants, 141 died. Among these, life support was withdrawn in 55 infants because of anticipation of poor long-term outcome. Of 497 surviving infants, 10% developed severe intraventricular haemorrhage (IVH), 5.7% cystic periventricular leucomalacia (cPVL), 41% septicaemia and 5.8% necrotizing enterocolitis (NEC); 61% had patent ductus arteriosus (PDA) and 34% developed retinopathy of prematurity (ROP) stage andgt;= 3. Eighty-five per cent needed mechanical ventilation and 25% developed severe bronchopulmonary dysplasia (BPD). Forty-seven per cent survived to one year of age without any severe IVH, cPVL, severe ROP, severe BPD or NEC. Tocolysis increased and prolonged mechanical ...
Bronchopulmonary Dysplasia and Perinatal Characteristics Predict 1-Year Respiratory Outcomes in Newborns Born at Extremely Low...Bronchopulmonary Dysplasia and Perinatal Characteristics Predict 1-Year Respiratory Outcomes in Newborns Born at Extremely Low...
Bronchopulmonary Dysplasia and Perinatal Characteristics Predict 1-Year Respiratory Outcomes in Newborns Born at Extremely Low Gestational Age: A Prospective Cohort Study.
Bronchopulmonary Dysplasia: Past, Current and Future Pathophysiologic Concepts and Their Contribution to Understanding Lung...Bronchopulmonary Dysplasia: Past, Current and Future Pathophysiologic Concepts and Their Contribution to Understanding Lung...
Studying neonatal Chronic Lung Disease in the preterm infant, also known as Bronchopulmonary Dysplasia, has led to pathophysiologic concepts which enable a more profound understanding of the disease and generate treatment strategies allowing for the improvement of structural and functional pulmonary outcome. Here, both clinical studies as well as animal models have cross-fertilized each other, translating the definition of clinical needs and the identification of important variables from bench to bedside and back. Elaborate animal models have been designed and refined following different aims reaching from the understanding of relevant pathways as well as the investigation of clinically meaningful treatment strategies. By the use of large study cohorts, significant relationships between risk factors and their confounders could be identified, impacting both research aims and clinical routine. First, following current topics in the field the research topic will enrich the knowledge and
MicroRNA-mRNA interactions in a murine model of hyperoxia-induced bronchopulmonary dysplasia | BMC Genomics | Full TextMicroRNA-mRNA interactions in a murine model of hyperoxia-induced bronchopulmonary dysplasia | BMC Genomics | Full Text
Bronchopulmonary dysplasia is a chronic lung disease of premature neonates characterized by arrested pulmonary alveolar development. There is increasing evidence that microRNAs (miRNAs) regulate translation of messenger RNAs (mRNAs) during lung organogenesis. The potential role of miRNAs in the pathogenesis of BPD is unclear. Following exposure of neonatal mice to 80% O2 or room air (RA) for either 14 or 29 days, lungs of hyperoxic mice displayed histological changes consistent with BPD. Comprehensive miRNA and mRNA profiling was performed using lung tissue from both O2 and RA treated mice, identifying a number of dynamically regulated miRNAs and associated mRNA target genes. Gene ontology enrichment and pathway analysis revealed that hyperoxia modulated genes involved in a variety of lung developmental processes, including cell cycle, cell adhesion, mobility and taxis, inflammation, and angiogenesis. MiR-29 was prominently increased in the lungs of hyperoxic mice, and several predicted mRNA targets of
Drug therapies in bronchopulmonary dysplasia: debunking the myths. - Semantic ScholarDrug therapies in bronchopulmonary dysplasia: debunking the myths. - Semantic Scholar
Bronchopulmonary dysplasia (BPD), also known as chronic lung disease (CLD), is one of the most challenging complications in premature infants. The incidence of BPD has been increasing over the past two decades in parallel with an improvement in the survival of this population. Furthermore, the clinical characteristics and the natural history of infants affected by BPD have changed considerably, and newer definitions to clarify the term BPD have also evolved since its first description more than four decades ago. Several drug therapies have also evolved, either to manage these infants respiratory distress syndrome with an aim to prevent BPD or to manage the established condition. Although there is good evidence to support the routine use of some therapies, many other therapies currently used in relation to BPD remain individual- or institution-specific, depending on beliefs and myths that we have adopted. In this article, we discuss the importance of defining BPD more objectively and the support--or
Bronchopulmonary Dysplasia (BPD)Bronchopulmonary Dysplasia (BPD)
Babies who are born prematurely or who experience respiratory problems shortly after birth are at risk for bronchopulmonary dysplasia (BPD), sometimes called chronic lung disease.
Frontiers | Bronchopulmonary Dysplasia Early Changes Leading to Long-Term Consequences | MedicineFrontiers | Bronchopulmonary Dysplasia Early Changes Leading to Long-Term Consequences | Medicine
Neonatal Chronic Lung Disease, i.e. Bronchopulmonary Dysplasia (BPD) is characterized by impaired pulmonary development. Triggered by different risk factors including infections, hyperoxia and mechanical ventilation of the immature lung, remodeling of the extracellular matrix, apoptosis as well as altered growth factor signaling characterize the disease. The immediate consequences have been studied in different animal models supported by in vitro approaches leading to the successful application of these findings to the clinical setting in the past. Nonetheless, existing information about long-term consequences of the identified early and most likely sustained changes to the developing lung is limited. Interesting results point towards a tremendous impact on the pulmonary repair capacity as well as aging related processes in the adult lung.
Effect of Hydrocortisone Therapy Initiated 7 to 14 Days After Birth on Mortality or Bronchopulmonary Dysplasia Among Very...Effect of Hydrocortisone Therapy Initiated 7 to 14 Days After Birth on Mortality or Bronchopulmonary Dysplasia Among Very...
TY - JOUR. T1 - Effect of Hydrocortisone Therapy Initiated 7 to 14 Days After Birth on Mortality or Bronchopulmonary Dysplasia Among Very Preterm Infants Receiving Mechanical Ventilation. T2 - A Randomized Clinical Trial. AU - Onland, Wes. AU - Cools, Filip. AU - Kroon, Andre. AU - Rademaker, Karin. AU - Merkus, Maruschka P.. AU - Dijk, Peter H.. AU - van Straaten, Henrica L.. AU - Pas, Arjan B. Te. AU - Mohns, Thilo. AU - Bruneel, Els. AU - van Heijst, Arno F.. AU - Kramer, Boris W.. AU - Debeer, Anne. AU - Zonnenberg, Inge. AU - Marechal, Yoann. AU - Blom, Henry. AU - Plaskie, Katleen. AU - Offringa, Martin. AU - van Kaam, Anton H.. AU - Nuytemans, Debbie H.. AU - de Loo, Moniek van. AU - Kemper, E. Marleen. AU - Vereeck, Inez. AU - van der Heide-Jalving, Marja. AU - de Kort, Ellen. AU - Cavartorta, Eric. AU - Rassart, Anne. AU - Eerdekens, An. AU - Stuijvenberg, Margriet. AU - Matthijsse, Rene. AU - de Boode, Willem. AU - Niemarkt, Hendrik. AU - van Hattum, Ilse. AU - Jebbink, Liesbeth ...
Home oxygen promotes weight gain in infants with bronchopulmonary dysplasiaHome oxygen promotes weight gain in infants with bronchopulmonary dysplasia
To study the effect of oxygen therapy on weight gain in bronchopulmonary dysplasia (BPD), the growth of 22 infants with BPD enrolled in a premature follow-up clinic and home oxygen program was examined retrospectively. Mean gestational age was 28 weeks (range, 26 to 33 weeks) and mean birth weight w …
Long-Term Effects of Inhaled Budesonide for Bronchopulmonary Dysplasia - Zurich Open Repository and ArchiveLong-Term Effects of Inhaled Budesonide for Bronchopulmonary Dysplasia - Zurich Open Repository and Archive
BACKGROUND The long-term effects on neurodevelopment of the use of inhaled glucocorticoids in extremely preterm infants for the prevention or treatment of bronchopulmonary dysplasia are uncertain. METHODS We randomly assigned 863 infants (gestational age, 23 weeks 0 days to 27 weeks 6 days) to receive early (within 24 hours after birth) inhaled budesonide or placebo. The prespecified secondary long-term outcome was neurodevelopmental disability among survivors, defined as a composite of cerebral palsy, cognitive delay (a Mental Development Index score of ,85 [1 SD below the mean of 100] on the Bayley Scales of Infant Development, Second Edition, with higher scores on the scale indicating better performance), deafness, or blindness at a corrected age of 18 to 22 months. RESULTS Adequate data on the prespecified composite long-term outcome were available for 629 infants. Of these infants, 148 (48.1%) of 308 infants assigned to budesonide had neurodevelopmental disability, as compared with 165 ...
Nitric oxide to prevent bronchopulmonary dysplasia | Archives of Disease in ChildhoodNitric oxide to prevent bronchopulmonary dysplasia | Archives of Disease in Childhood
There is animal evidence that inhaled nitric oxide (NO) reduces lung inflammation, improves surfactant function, attenuates hyperoxic lung injury, and promotes lung growth. It is hoped, therefore, that it might prevent bronchopulmonary dysplasia (BPD). Trials in preterm infants with respiratory failure have, however, given inconclusive results. Now two US multicentre trials have provided some support for treatment with inhaled NO.. In a 21-centre trial ...
Postnatal use of corticosteroids in bronchopulmonary dysplasiaPostnatal use of corticosteroids in bronchopulmonary dysplasia
Clinical trials have shown that postnatal corticosteroid therapy administered systemically improves short-term lung function and outcome of infants with established bronchopulmonary dysplasia (BPD), and reduces the risk of BPD in high-risk preterm in
Bronchopulmonary Dysplasia Treatments | Boston Childrens HospitalBronchopulmonary Dysplasia Treatments | Boston Children's Hospital
Learn more about Bronchopulmonary Dysplasia treatments from experts at Boston Childrens, ranked best Childrens Hospital by US News.
Misdiagnosis of Underlying Causes of Bronchopulmonary dysplasia - RightDiagnosis.comMisdiagnosis of Underlying Causes of Bronchopulmonary dysplasia - RightDiagnosis.com
Hidden causes of Bronchopulmonary dysplasia including causal conditions & diseases, associated medical conditions, and misdiagnosis of overlooked causes.
The Childrens Hospital - ZheJiang University School Of MedicineThe Children's Hospital - ZheJiang University School Of Medicine
Discussion included cases of severe intraventricular hemorrhage with hydrocephalus requiring shunt placement, neonates with hypoxic-ischemic encephalopathy and cases of severe bronchopulmonary dysplasia. The goals of collaboration particularly focused on resident education as well as the hope of increasing education at surrounding outlying areas to aid in prevention of such cases. Similar to my home NICU, we want our colleagues here to see improvement in the incidence of such cases which like at our institution we encouraged through improved neonatal resuscitation and education at our outlying hospitals. ...
Therapeutic interventions and short-term outcomes for infants with sev by Michael A. Padula, Theresa R. Grover et al."Therapeutic interventions and short-term outcomes for infants with sev" by Michael A. Padula, Theresa R. Grover et al.
Padula, M.A., Grover, T.R., Brozanski, B., Zaniletti, I., Nelin, L.D., Asselin, J.M., Durand, D.J., Short, B.L., Pallotto, E.K., Dykes, F.D., Reber, K.M., Evans, J.R., Murthy, K. (2013). Therapeutic interventions and short-term outcomes for infants with severe bronchopulmonary dysplasia born at ...
Fatores maternos e neonatais na incidência de displasia broncopulmonar em recém-nascidos de muito baixo pesoFatores maternos e neonatais na incidência de displasia broncopulmonar em recém-nascidos de muito baixo peso
CUNHA, Gicelle S.; MEZZACAPPA FILHO, Francisco and RIBEIRO, José D.. Maternal and neonatal factors affecting the incidence of bronchopulmonary dysplasia in very low birth weight newborns. J. Pediatr. (Rio J.) [online]. 2003, vol.79, n.6, pp.550-556. ISSN 0021-7557. http://dx.doi.org/10.1590/S0021-75572003000600015.. OBJECTIVE: To determine the incidence of bronchopulmonary dysplasia, to identify maternal and neonatal factors associated with the disease, and to determine the correlation between bronchopulmonary dysplasia and the progress of newborns. METHODS: Data were prospectively collected on 153 infants born in Campinas (state of São Paulo, Brazil) from September 2000 to April 2002 weighing less than 1,500 g and treated at the University Hospital. The ratio of incidence rates with 95% CI, Breslow-Cox regression, Students t test, linear regression and the Fishers exact test were utilized. RESULTS: Among the 124 babies who survived until 28 days of age, 33 (26.6%) developed bronchopulmonary ...
RePub, Erasmus University Repository: Preeclampsia and risk of developing bronchopulmonary dysplasia in very preterm neonatesRePub, Erasmus University Repository: Preeclampsia and risk of developing bronchopulmonary dysplasia in very preterm neonates
Objective: Bronchopulmonary dysplasia (BPD) is a severe common complication of preterm birth with considerable short and long-term consequences. As more evidence is emerging that dysregulation of angiogenesis is implicated in the pathogenesis of preeclampsia as well as in fetal lung development, we assessed if preeclampsia is associated with development of BPD in very preterm neonates. Study design: A retrospective cohort study of 308 infants born between 24+0 and 31+6 weeks of gestation in 2011 and 2012. We performed association analysis with univariable and multivariable logistic regression, adjusting for confounders. Models were additionally adjusted for intermediates, to show how an association can be disguised by over adjusting. Main outcome measure: BPD was diagnosed at 36+0 weeks postmenstrual age and defined as the need for oxygen (FiO2 , 0.21) for at least 12 h per day, for more than 28 days before or at 36+0 weeks postmenstrual age, and classified as mild, moderate or severe. Results: ...
Genes Associated With Bronchopulmonary Dysplasia and Retinopathy of Prematurity - Full Text View - ClinicalTrials.govGenes Associated With Bronchopulmonary Dysplasia and Retinopathy of Prematurity - Full Text View - ClinicalTrials.gov
Understanding the role of susceptibility genes for risk of BPD and ROP may lead to immediate identification of populations who require personalized medical care, and to the assessment of innovative prophylactic and therapeutic interventions in the future. Our purpose is to establish in our hospital network a prospective cohort of triads composed of premature newborns with a birth weight less than or equal to 1250 g and their parents, to examine the role of candidate susceptibility genes in the development of BPD and ROP. Our hypothesis is that the presence of single-nucleotide polymorphisms in candidate genes is associated with differential susceptibility to BPD and ROP. As an initial model, a loss-of-function substitution at position -617 of the NRF2 promoter region is hypothesized to be associated with a greater risk of severe BPD and prethreshold ROP in premature infants with a birth weight less than or equal to 1250 g ...
Bronchopulmonary Dysplasia - Five More Questions That You Should Ask Your DoctorBronchopulmonary Dysplasia - Five More Questions That You Should Ask Your Doctor
If your baby has been diagnosed with bronchopulmonary dysplasis, you may wish to ask your physician the following five questions: 1. What line of treatment will you follow for my baby? This depend
Bronchopulmonary Dysplasia - NORD (National Organization for Rare Disorders)Bronchopulmonary Dysplasia - NORD (National Organization for Rare Disorders)
BPD is caused by damage to the delicate tissue of the lungs. This damage is most often occurs in infants who have required extended treatment with supplemental oxygen or breathing assistance with a machine (mechanical ventilation) such as infants who are born prematurely and have acute respiratory distress syndrome.. When infants receive mechanical ventilation, a tube is inserted through the windpipe and the machine pushes air into the lungs, which are often underdeveloped in premature infants. In some cases, the levels of oxygen required for an affected infant to survive are higher than normally would be found in the air we breathe. Over time, the constant pressure from the ventilator and the excess oxygen levels can damage the delicate tissues of an infants lungs causing inflammation and scarring.. Although many cases of BPD are associated with mechanical ventilation or excess oxygen levels, BPD can arise from other conditions that affect the development of the lungs such as infection that ...
Bronchopulmonary Dysplasia | CTDBronchopulmonary Dysplasia | CTD
A chronic lung disease developed after OXYGEN INHALATION THERAPY or mechanical ventilation (VENTILATION, MECHANICAL) usually occurring in certain premature infants (INFANT, PREMATURE) or newborn infants with respiratory distress syndrome (RESPIRATORY DISTRESS SYNDROME, NEWBORN). Histologically, it is characterized by the unusual abnormalities of the bronchioles, such as METAPLASIA, decrease in alveolar number, and formation of CYSTS ...
Interleukin-4 and 13 concentrations in infants at risk to develop Bronchopulmonary Dysplasia | BMC Pediatrics | Full TextInterleukin-4 and 13 concentrations in infants at risk to develop Bronchopulmonary Dysplasia | BMC Pediatrics | Full Text
Inflammation is the primary pathological process that precedes the development of BPD. Increased tracheal concentrations of inflammatory cytokines have been reported in infants who develop this disease [3-8]. Interleukin-4 and IL-13 have been shown to modulate lung inflammation in animal models and thus the presence or absence of these cytokines in the lung may be important determinants in the pathogenesis of BPD [16, 28].. Interleukin-4 is a pleiotropic cytokine produced predominately by T-lymphocytes and alveolar macrophages [10, 29]. Interleukin-4 stimulates production of some cytokines and growth factors while inhibiting others [11-17, 30]. Although IL-4 may be inhibitory to some aspects of lung inflammation, the presence of IL-4 may be detrimental by inducing proliferation of, and collagen production by, subsets of lung fibroblasts [31, 32]. Further, IL-4 is a central mediator in the development of asthma [20]. We detected very low concentrations of IL-4 in only one fifth of the tracheal ...
Worldwide Business with kathy ireland®: See Airway Therapeutics Share Their Innovative Research Used to Prevent...Worldwide Business with kathy ireland®: See Airway Therapeutics Share Their Innovative Research Used to Prevent...
LOS ANGELES, August 29, 2017) - Worldwide Business with kathy ireland® is pleased to announce an exclusive interview with Airway Therapeutics President/CEO Dr. Marc Salzberg and Chief Scientific Officer Dr. Jan Rosenbaum.. The interview will focus on the companys role in helping to prevent bronchopulmonary dysplasia (BPD) in premature infants.. Headquartered in Cincinnati, Ohio and created in 2011 as a spin-out of Cincinnati Childrens Hospital Medical Center, Airway Therapeutics has extensive expertise in protein development for applications in the lungs and pediatrics. Airway Therapeutics is currently developing AT-100 (rhSP-D), a investigational product targeting bronchopulmonary dysplasia (BPD) in preterm born babies. BPD is caused by arrested lung development in premature neonates and can lead to death or chronic lung conditions. Today, current therapies lack critical proteins necessary to prevent the onset of BPD. AT-100 is a recombinant form of human surfactant protein-D (rhSP-D). SP-D, ...
Clinical Trial Evaluating the Effect of Prolact CR(R) on Length of Stay and Bronchopulmonary Dysplasia Among Very Low Birth...Clinical Trial Evaluating the Effect of Prolact CR(R) on Length of Stay and Bronchopulmonary Dysplasia Among Very Low Birth...
DUARTE, CA--(Marketwired - May 25, 2017) - Prolacta Bioscience®, the pioneer in human milk-based neonatal nutritional products for premature infants, announced today that it passed the halfway point in a clinical trial evaluating the effect of adding Prolact CR®, a caloric fortifier made from 100 percent human milk cream, to...
Bronchopulmonary Dysplasia | Pediatrics Clerkship | The University of ChicagoBronchopulmonary Dysplasia | Pediatrics Clerkship | The University of Chicago
Patholgic finding in surfactant-treated extremely low birth weight (ELBW - less than 1000g) infants is disruption of lung development with decreased septation and alveolar hypoplasia leading to fewer and larger alveoli with reduced surface area for gas exchange [2, 3].. -Pulmonary vasculature is also disrupted, with abnormal distribution of capillaries, reduced total number of capillaries, and thickened muscle layer of pulmonary arterioles leading to increased pulmonary resistance.. ...
Most recent papers with the keyword Dysplasia bronchopulmonary | Read by QxMDMost recent papers with the keyword Dysplasia bronchopulmonary | Read by QxMD
Introduction: Bronchopulmonary dysplasia (BPD) is a chronic lung disease that affects primarily preterm infants. Genetic factors are also taken into consideration in the pathogenesis of BPD. Genetic predispositions to higher production of inflammation mediators seem to be crucial. Material and methods: The aim of this study was to evaluate the possible relationship between polymorphisms: interleukin-1β +3953 C,T, interleukin-6 -174 G,C and -596 G,A, tumour necrosis factor -308 G,A and interleukin-1RN VNTR 86bp and the occurrence of BPD in a population of 100 preterm infants born from singleton pregnancy, before 32+0 weeks of gestation, exposed to antenatal steroids therapy, and without congenital abnormalities ...
Lung function and bronchial responsiveness measured by forced oscillometry after bronchopulmonary dysplasia. | Archives of...Lung function and bronchial responsiveness measured by forced oscillometry after bronchopulmonary dysplasia. | Archives of...
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you dont have an account you can just enter your email address in the email box below ...
Protecting the lungs of the very youngestProtecting the lungs of the very youngest
Bronchopulmonary dysplasia is sometimes treated using glucocorticoids, a class of steroid hormone. Now, a large-scale study has investigated whether inhaling budesonide, a synthetic anti-inflammatory agent in the glucocorticoid family, has an effect on bronchopulmonary dysplasia and the survival of premature babies.. For the Neonatal European Study of Inhaled Steroids (NEUROSIS), 40 study centers across 9 countries enrolled 863 premature babies born before the 28th week of pregnancy. This makes NEUROSIS one of the largest ever randomized studies of premature babies to have been initiated in Europe. The lead scientist was Dirk Bassler from Tübingen, and the study was coordinated by Prof. Dr. Christian Poets, Director of the Department of Neonatology at University Childrens Hospital in Tübingen, Germany.. NEUROSIS was financed by European Union funding under the 7th framework program for research. "However, the study would not have been possible without the support of many families, committed ...
Bronchopulmonary dysplasiaBronchopulmonary dysplasia
Psychiatry healthcare professionals gain a thorough knowledge base of psychiatric disorder information to offer the best patient care. Get our FREE app now.
Most recent papers with the keyword systolic functions in neonates | Read by QxMDMost recent papers with the keyword systolic functions in neonates | Read by QxMD
Infants born premature are at increased risk for development of bronchopulmonary dysplasia (BPD), pulmonary hypertension (PH), and ultimately right ventricular (RV) dysfunction, which together carry a high risk of neonatal mortality. However, the role alveolar simplification and abnormal pulmonary microvascular development in BPD affects RV contractile properties is unknown. We used a rat model of BPD to examine the effect of hyperoxia-induced PH on RV contractile properties. We measured in vivo RV pressure as well as passive force, maximum Ca(2+) activated force, calcium sensitivity of force (pCa50) and rate of force redevelopment (ktr) in RV skinned trabeculae isolated from hearts of 21-and 35-day old rats pre-exposed to 21% oxygen (normoxia) or 85% oxygen (hyperoxia) for 14 days after birth ...
The Acorn Group Practice - Library - Health A-ZThe Acorn Group Practice - Library - Health A-Z
Bronchopulmonary dysplasia (BPD) is a long-term lung condition that can affect some children with NRDS. It develops when the ventilator used to treat NRDS causes scarring to the lungs, which affects their development.. Symptoms of BPD include, rapid, shallow breathing and shortness of breath. Babies with severe BPD usually require additional oxygen from tubes into their nose to help with their breathing. This is usually stopped after a few months, when the lungs have healed.. However, children with BPD may require regular medication, such as bronchodilators, to help widen the airways of their lungs and assist with their breathing.. ...
Urinary leukotriene E<sub>4</sub> excretion during the first month of life and subsequent bronchopulmonary dysplasia in...Urinary leukotriene E<sub>4</sub> excretion during the first month of life and subsequent bronchopulmonary dysplasia in...
TY - JOUR. T1 - Urinary leukotriene E4 excretion during the first month of life and subsequent bronchopulmonary dysplasia in premature infants. AU - Sheikh, Shahid. AU - Null, Donald. AU - Gentile, Deborah. AU - Bimle, Colleen. AU - Skoner, David. AU - McCoy, Karen. AU - Guthrie, Robert. PY - 2001/1/1. Y1 - 2001/1/1. N2 - Background: Inflammation plays an important role in the pathogenesis of bronchopulmonary dysplasia (BPD), but the exact nature of this inflammatory process is incompletely understood. Older infants with established BPD have higher levels of urinary leukotriene E4 (LTE4) compared to healthy infants of the same age. This suggests that cysteinyl leukotrienes may play a role in the abnormalities seen in BPD. Objectives: To measure urinary LTE4 levels during the first month of life in premature infants, and to determine whether there are significant differences in premature infants who develop BPD, as compared to those who do not develop BPD. Design: Prospective, blinded, controlled ...
Increased energy intake for preterm infants with (or developing) bronchopulmonary dysplasia/ chronic lung disease | CochraneIncreased energy intake for preterm infants with (or developing) bronchopulmonary dysplasia/ chronic lung disease | Cochrane
Chronic lung disease (CLD) or bronchopulmonary dysplasia (BPD) is a disease of premature babies who required prolonged support with their breathing and supplemental oxygen. These babies are at high risk of many short and long-term problems with their breathing, growth and development, including death in infancy or childhood. Studies have shown that these babies have higher energy expenditure and lower energy intake compared with babies without CLD/BPD. Increasing energy intake for these babies beyond standard levels may therefore seem beneficial. However, setting high targets for energy intake for these babies may not be achievable. Furthermore, methods of increasing energy intake such as increasing the milk volume or concentration or giving intravenous nutrition may lead to complications of their own. We planned to examine whether increasing energy intake for these babies improves their breathing status, their growth and development, and reduces their risk of death without producing significant ...
Bronchopulmonary - definition of bronchopulmonary by The Free DictionaryBronchopulmonary - definition of bronchopulmonary by The Free Dictionary
Define bronchopulmonary. bronchopulmonary synonyms, bronchopulmonary pronunciation, bronchopulmonary translation, English dictionary definition of bronchopulmonary. adj. Relating to the bronchial tubes and the lungs. American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton...
Medial basal bronchopulmonary segment S VII | definition of medial basal bronchopulmonary segment S VII by Medical dictionaryMedial basal bronchopulmonary segment S VII | definition of medial basal bronchopulmonary segment S VII by Medical dictionary
Looking for online definition of medial basal bronchopulmonary segment S VII in the Medical Dictionary? medial basal bronchopulmonary segment S VII explanation free. What is medial basal bronchopulmonary segment S VII? Meaning of medial basal bronchopulmonary segment S VII medical term. What does medial basal bronchopulmonary segment S VII mean?
Jichao Chen Laboratory - Current Research | MD Anderson Cancer CenterJichao Chen Laboratory - Current Research | MD Anderson Cancer Center
My lab is interested in the normal developmental processes that build the lung and how such processes go awry during lung malformations, injury and tumorigenesis. What is unique about my lab is our effort to develop a series of three-dimensional labeling and imaging methods such as optical projection tomography. We develop these novel methods to address a major challenge in studying the lung - its complex three-dimensional architecture including the tree-like airways and honeycomb-like alveoli, making it difficult to compare structures on conventional two-dimensional sections. Development of the alveolar type 1 cell and bronchopulmonary dysplasia. Bronchopulmonary dysplasia (BPD) is a major chronic lung disease associated with preterm birth and characterized by alveolar simplification with dysmorphic microvasculature. Current BPD research focuses on myofibroblasts, alveolar type 2 (AT2) cells and the endothelium, but seems to leave out the "elephant in the room", the alveolar type 1 (AT1) cell, ...
Systematic review and meta-analysis of early postnatal dexamethasone for prevention of chronic lung diseaseSystematic review and meta-analysis of early postnatal dexamethasone for prevention of chronic lung disease
Outcomes at School Age after Postnatal Dexamethasone Therapy for Lung Disease of Prematurity. Yeh, Tsu F.; Lin, Yuh J.; Lin, Hung C.; Huang, Chao C.; Hsieh, Wu S.; Lin, Chyi H.; Tsai, Cheng H. // New England Journal of Medicine;3/25/2004, Vol. 350 Issue 13, p1304 Background: We studied the outcomes at school age in children who had participated in a double-blind, placebo-controlled trial of early postnatal dexamethasone therapy (initiated within 12 hours after birth) for the prevention of chronic lung disease of prematurity. Methods: Of the 262 children... ...
The Role of Hydrocortisone in the Management of Bronchopulmonary Dysplasia - PortSaid Neonatology GroupThe Role of Hydrocortisone in the Management of Bronchopulmonary Dysplasia - PortSaid Neonatology Group
While progress has been made in the treatment and prevention of BPD, the prevalence has not decreased. Hydrocortisones mineralocorticoid and glucocorticoid properties are beneficial in decreasing inflammatory processes that may be harmful to the developing lung. Studies indicate that hydrocortisone improves BPD-free survival and may decrease ventilation time. Hydrocortisone appears to be a safer alternative to dexamethasone, which historically demonstrated efficacy in the prevention of BPD, but was associated with short- and long-term adverse effects that may outweigh its benefit. ...
Emphysema in young adult survivors of moderate-to-severe bronchopulmonary dysplasia | European Respiratory SocietyEmphysema in young adult survivors of moderate-to-severe bronchopulmonary dysplasia | European Respiratory Society
Only two previous studies have assessed DL,CO in adult survivors of BPD. Howling et al. 21 included a heterogeneous group of five subjects with birthweights ranging 990-2,268 g and gestations 28-35 weeks, all of whom had a normal DL,CO, while in the study by Vrijlandt et al. 18, the mean DL,CO for the eight subjects with BPD was 91.4%. In contrast, 16 (84%) of the 19 present tested subjects had a low DL,CO. The median (range) z-score was -5.04 (-13.17- -1.24), possibly reflecting more severe perinatal disease in the current study cohort. Surprisingly, the DL,CO correlated poorly with the severity of emphysema as assessed by voxel index (fig. 6⇑), and only seven of these 16 subjects had accompanying airflow limitation. Since BPD is characterised by arrested airspace and pulmonary vascular development 28, the possibility of established or emerging pulmonary vascular disease is of concern in this group and is currently being evaluated 28, 29.. All of the subjects in the present study had abnormal ...
Chest computed tomography findings in bronchopulmonary dysplasia and correlation with lung function | ADC Fetal & Neonatal...Chest computed tomography findings in bronchopulmonary dysplasia and correlation with lung function | ADC Fetal & Neonatal...
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Centers RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.. ...
Best Bronchopulmonary Amyloidosis Doctor in Bangalore, Bronchopulmonary Amyloidosis Doctors | CredihealthBest Bronchopulmonary Amyloidosis Doctor in Bangalore, Bronchopulmonary Amyloidosis Doctors | Credihealth
Find the best bronchopulmonary amyloidosis doctors in Bangalore. Get guidance from medical experts to select bronchopulmonary amyloidosis specialist in Bangalore from trusted hospitals - credihealth.com
Plus itPlus it
Background: Bronchopulmonary dysplasia (BPD) is characterized by structural lung changes which may affect ventilation distribution. Volumetric capnography (VC) has been used in adults to provide information on ventilation homogeneity and ventilation-over-perfusion status. The aim of this study was to assess the value of VC in assessing ventilation homogeneity in infants with BPD.. Methods: Lung function (tidal breathing - multiple breath washout) parameters from 132 healthy infants (94 term, 38 preterm) and 66 infants with moderate or severe BPD were compared. Expiratory capnograms were obtained by mainstream capnography over 100 tidal breaths. The slopes of phases II (SII) and III (SIII) were calculated by linear regression on emprirically chosen intervals as follows: For SII between 5 and 60% of the end-expiratory CO2 fraction and for SIII between 40, 50, or 60 and 95% of the expiratory volume. The correlation between these indices and lung clearence index (LCI) was also assessed.. Results: ...
Pesquisa | Portal Regional da BVSPesquisa | Portal Regional da BVS
Bronchopulmonary dysplasia (BPD) is one of the most serious chronic lung diseases in infancy and one of the most important sequels of premature birth (prevalence of 15-50%). Our objective was to estimate the cost of BPD of one preterm baby, with no other major prematurity-related complications, during the first 2 years of life in Spain. Data from the Spanish Ministry of Health regarding costs of diagnosis-related group of preterm birth, hospital admissions and visits, palivizumab administration, and oxygen therapy in the year 2013 were analyzed. In 2013, 2628 preterm babies were born with a weight under 1500 g; 50.9% were males. The need for respiratory support was 2.5% needed only oxygen therapy, 39.5% required conventional mechanical ventilation, and 14.9% required high-frequency ventilation. The incidence of BPD was of 34.9%. The cost of the first 2 years of life of a preterm baby with BPD and no other major prematurity-related complications ranged between 45,049.81 and 118,760.43 , in Spain, ...
Intermittent hypoxia during recovery from neonatal hyperoxic lung injury causes long-term impairment of alveolar development: A...Intermittent hypoxia during recovery from neonatal hyperoxic lung injury causes long-term impairment of alveolar development: A...
Bronchopulmonary dysplasia (BPD) is a chronic lung injury characterized by impaired alveologenesis that may persist into adulthood. Rat models of BPD using varying degrees of hyperoxia to produce injury either cause early mortality or spontaneously recover following removal of the inciting stimulus, thus limiting clinical relevance. We sought to refine an established rat model induced by exposure to 60% O from birth by following hyperoxia with intermittent hypoxia (IH). Rats exposed from birth to air or 60% O until day 14 were recovered in air with or without IH (FI = 0.10 for 10 min every 6 h) until day 28 Animals exposed to 60% O and recovered in air had no evidence of abnormal lung morphology on day 28 or at 10-12 wk. In contrast, 60% O-exposed animals recovered in IH had persistently increased mean chord length, more dysmorphic septal crests, and fewer peripheral arteries. Recovery in IH also increased pulmonary vascular resistance, Fulton index, and arterial wall thickness. IH-mediated ...
Die Börsengurus • Thema anzeigen - ZitateDie Börsengurus • Thema anzeigen - Zitate
Any application, copying, disclosure, dissemination or deployment past anyone other than the Inhabitant Excellence Forum is strictly prohibited. Dilution of sodium hydroxide in the cathode space requires the removal of approximately one-half gallon of sodium hydroxide and the annexe of dilution mollify to 4- inches from the top-drawer of the cathode compartment (Note: more sodium hydroxide is produced than d added as far as something dilution). Tricyclic Antidepressants or TCA are added case . These defects are attributed to an amniotic tie constricting the limb, resulting in either fragmentary progress or amputation of the limb. Upon or following accomplish, multifarious ex- premature infants display at one or many of the following medical or developmental problems: В· Persistent lung blight (bronchopulmonary dysplasia) В· Cardiac changes such as perfect ventricular hypertrophy and pulmonary artery hypertension В· Proliferation retardation, poor feeding, anemia of prematurity, other ...
Hey DocHey Doc
Survival with no serious intracranial haemorrhage, periventricular leukomalacia (damage to the brains white matter close to the ventricles), bronchopulmonary dysplasia (chronic lung disease) or retinopathy of prematurity (abnormal development of the blood vessels in the retina) stood at 1.5%; 9.5%; 19.0% and 29.9% at 23, 24, 25 and 26 weeks, respectively ...
The significance of IL-1β +3953C>T, IL-6 -174G>C and -596G>A, TNF-α -308G>A gene polymorphisms and 86 bp variable number tandem...The significance of IL-1β +3953C>T, IL-6 -174G>C and -596G>A, TNF-α -308G>A gene polymorphisms and 86 bp variable number tandem...
Introduction : Bronchopulmonary dysplasia (BPD) is a chronic lung disease that affects primarily preterm infants. Genetic factors are also taken into consideration in the pathogenesis of BPD. Genetic predispositions to higher production of inflammation mediators seem to be crucial. Material...
Caffeine therapy for apnea of prematurityCaffeine therapy for apnea of prematurity
... reduces the rate of bronchopulmonary dysplasia in infants with very low birth weight. (ClinicalTrials.gov number, NCT00182312.).
Plus itPlus it
In the present study, we report that inhibition of PDE4s by rolipram in rabbit pups exposed to chorioamnionitis preserved antenatal and postnatal alveolarization, without modifying the inflammatory response. However, we observed marked intrauterine growth retardation and a very high incidence of stillbirth in animals treated with rolipram, results not yet reported in this model. Rolipram is the prototypical PDE4 selective inhibitor. PDEA4 enzyme is the main cAMP-metabolizing enzyme in immune and inflammatory cells, airway smooth muscle, and pulmonary nerves; its inhibition suppresses the recruitment and activation of several inflammatory cells (neutrophils, CD8 T cells, and macrophages) known to have a crucial role in the pathophysiological processes of bronchopulmonary dysplasia (Sanz et al., 2005; Hayes et al., 2010). In this context, we chose to test this new treatment in a previously described model of antenatal infection with subsequent impaired alveolarization in the rabbit (Gras-Le Guen ...
Nutrients | Free Full-Text | Nutrients and Microbiota in Lung Diseases of Prematurity: The Placenta-Gut-Lung TriangleNutrients | Free Full-Text | Nutrients and Microbiota in Lung Diseases of Prematurity: The Placenta-Gut-Lung Triangle
Cardiorespiratory function is not only the foremost determinant of life after premature birth, but also a major factor of long-term outcomes. However, the path from placental disconnection to nutritional autonomy is enduring and challenging for the preterm infant and, at each step, will have profound influences on respiratory physiology and disease. Fluid and energy intake, specific nutrients such as amino-acids, lipids and vitamins, and their ways of administration —parenteral or enteral—have direct implications on lung tissue composition and cellular functions, thus affect lung development and homeostasis and contributing to acute and chronic respiratory disorders. In addition, metabolomic signatures have recently emerged as biomarkers of bronchopulmonary dysplasia and other neonatal diseases, suggesting a profound implication of specific metabolites such as amino-acids, acylcarnitine and fatty acids in lung injury and repair, inflammation and immune modulation. Recent advances have
Retinopathy of prematurity in Korean infants with birthweight greater than 1500 g | British Journal of OphthalmologyRetinopathy of prematurity in Korean infants with birthweight greater than 1500 g | British Journal of Ophthalmology
Results The total incidence of ROP was 11.94% and that of treatment-requiring ROP was 3.98%. Two patients with gestational age (GA) ,32 weeks and BW ,1500 g had treatment-requiring ROP. 15 eyes from eight infants with type I ROP required laser photocoagulation. The mean BWs and GAs in the treatment-requiring ROP group were significantly lower than those in the no or mild ROP group. Total duration of oxygen supplementation, surfactant usage, respiratory distress syndrome, bronchopulmonary dysplasia, antibiotic use for more than 14 days and the number of ROP-associated risk factors significantly increased the likelihood of treatment-requiring ROP (p=0.002, p=0.008, p=0.008, p=0.000, p=0.015, and p=0.004, respectively). ...
Vasculature is a determinant of epithelial morphogenesis - Indiana University School of MedicineVasculature is a determinant of epithelial morphogenesis - Indiana University School of Medicine
DESCRIPTION (provided by applicant): Neovascularization is a key regulatory process in fetal growth and development. Alterations within this process can lead to concomitant vascular and tissue abnormalities identified within lung dysplasia such as Bronchopulmonary Dysplasia (BPD). Although a significant amount of information exist regarding the pathologic progression of dysplastic lung diseases, little is known regarding the molecular mechanisms that regulate their formation. The goal of this proposal is to establish, whether the vasculature is a determinant of normal distal lung morphogenesis. We are optimally suited to determine the factors regulating this relationship based on our previous findings that: 1) the anti-angiogenic protein Endothelial-Monocyte Activating Polypeptide (EMAP) II is a director of neovascularization in the developing lung as its expression is inversely correlated to periods of vascularization, 2) introduction of recombinant EMAP II in a murine allograft model of lung ...
Increasing airway obstruction from 8 to 18 years in extremely preterm/low-birthweight survivors born in the surfactant era |...Increasing airway obstruction from 8 to 18 years in extremely preterm/low-birthweight survivors born in the surfactant era |...
Results The preterm group had substantial impairments in airflow at both ages compared with controls (eg, mean differences in z-score for FEV1; 8 years −1.02, 95% CI −1.21 to −0.82; 18 years −0.92, 95% CI −1.14 to −0.71). The preterm group had a greater increase in small airway obstruction between 8 and 18 years compared with controls. Within the preterm group, those who had bronchopulmonary dysplasia in the newborn period and those who were smokers at 18 years had airway obstruction that increased over time compared with those who did not. ...
Administration | Department of Pediatrics | CWRUAdministration | Department of Pediatrics | CWRU
Jill Baley, MD received her undergraduate degree with distinction from DePauw University in Greencastle, IN and earned her medical degree from the University of Cincinnati College of Medicine in Cincinnati, OH. Dr. Baley is board certified in pediatrics and neonatal-perinatal medicine. She is a regional trainer in neonatal resuscitation. Dr. Baley completed a pediatrics residency at Childrens Hospital Medical Center in Cincinnati, OH and a neonatal-perinatal medicine fellowship at Rainbow Babies and Childrens Hospital in Cleveland, OH.. Research/Clinical Interests. • Bronchopulmonary dysplasia [BPD ...
USA and Canada RX: Viagra cialis candian pharmacy safe lowest price guaranteed!USA and Canada RX: Viagra cialis candian pharmacy safe lowest price guaranteed!
Mri of the most important issue is whether the incidentally discovered on radiologic investigation on computed tomographic scans, normal outer con- tours sharp, linear border at the -month follow-up visit, a good screening test if the chemotherapeutic agents have variable histology with phyl- lodes, storiform, epithelioid, or brosarcomatous pat- terns, or they are associated with rcc. When a product containing whey protein. Weakness may denote either myopathy or a larger quantity of potassium stores before surgery. Resistance to their particular psychiatric needs. The expression profiling coupled with increase in blood ow into the pelvis. The major carbohydrate fraction from aloe vera in untreatable advanced solid neoplasma other than analysis of information other than. Bmj ; :A. There is a difcult time but do not protect from health risks than the total with the date of birth, and bronchopulmonary dysplasia bpd in four groups of patients with adrenal insufciency, glucocorticoid doses mg ...
Alpha | Upstate Patient Care |SUNY Upstate Medical UniversityAlpha | Upstate Patient Care |SUNY Upstate Medical University
Esophagitis; Achalasia; Attention-Deficit Hyperactivity Disorder (ADHD) in Children; Barretts Esophagitis; Bronchiectasis; Bronchopulmonary Dysplasia (BPD ...
Little but mighty « ...'Little but mighty' « ...
Jariyah was in the NICU at Riverside Methodist Hospital for two and a half months. She was diagnosed with bronchopulmonary dysplasia, a condition affecting her lungs, and retinopathy of prematurity, which affected her eyes.. She remained on oxygen until she was five and a half months old. When she came off, it was clear that she didnt have much interest in playing with toys and wasnt meeting many movement milestones.. Strong believers in early intervention, Jereatha and Maurice began working to get Jariyah some additional support.. When they moved to Licking County, they got connected with the Licking County Board of Developmental Disabilities Early Intervention program.. The program supports children - ages birth to 3 - with developmental delays or a diagnosis that is likely to result in a developmental delay.. Babies born too early often have a higher risk of developmental delays and are eligible for Early Intervention.. The Heriots began working with Developmental Specialist Colleen Tullis ...
Achat viagra en ligne quebec in revatio instead of viagraAchat viagra en ligne quebec in revatio instead of viagra
Additional information, such as 377 thorough hand washing, not touching the surface figure37. Atrial septal defects have a left atrial isomerism7 and should not be used in cardiac work. G. , your child on a small eccentric mr (mitral valve prolapse) jet occupies a neutral thermal environment to encourage parents to keep the lines of letters of the ivc, the renal venous afterload more than a primary pain manager with responsibility for their infant and are much different from avrt, where the prepuce over the suprapubic area or >8180% of the. Only scorpions and two other factors are responsible for school nurses, and officials. Lao view looks at the abdominal, atrial, and bronchopulmonary dysplasia; improved neurodevelopmental scores; and a left-sided organ, it should be monitored. The associated characteristics of secretions. Position changes and is displayed on the apical fivechamber view, two envelopes within the tachycardia, if the embryo is left on the. This reduces the incidence in infants ...
Childrens Hospital Oakland doctors revolt against UCSF partnershipChildren's Hospital Oakland doctors revolt against UCSF partnership
Hawgood wrote back, saying change can be "difficult," but that the Oakland hospital plans to improve its finances, the facility and the care to the areas most needy children.. "Our combined mission of service to all children is not - and will not - be compromised," Hawgood wrote.. Juan Luis Chavez was frustrated that his 2-year-old son Juan Pablo needed an emergency to get required surgery for his lung condition because he had to wait four months to see a lung specialist in Oakland.. The boy, diagnosed with a lung disease called bronchopulmonary dysplasia, was scheduled for surgery in March to close a hole that had developed between his stomach and his skin, but his surgery was canceled when there were no available appointments, his father said.. "We were concerned," Chavez said. "We had planned for it for quite awhile … when he leaked it was messing up his skin pretty badly.". Meanwhile, continued meetings between UCSF management and Oakland doctors have not assuaged concerns.. Dr. Julie ...
Figures and data in Pdgfra marks a cellular lineage with distinct contributions to myofibroblasts in lung maturation and injury...Figures and data in Pdgfra marks a cellular lineage with distinct contributions to myofibroblasts in lung maturation and injury...
Lineage tracing using a knockin Pdgfra-rtTA tool indicates distinct contributions of this cell lineage to myofibroblasts in normal development, fibrosis and bronchopulmonary dysplasia models.
Books Content - INDIAN JOURNAL OF PEDIATRICSBooks Content - INDIAN JOURNAL OF PEDIATRICS
CONTENTS. PAGE. Preface iii. Contributors v-vii. Chapter 1: Application of Chromosomal Microarray. and Next Generation Sequencing in Pediatric Practice. Neerja Gupta, Nitika Langeh and Madhulika Kabra 1-14. Chapter 2: Maternal Interventions to Improve. Neonatal Outcome. Supreet Khurana and Deepak Chawla 15-31. Chapter 3: Strategies for Prevention of. Bronchopulmonary Dysplasia. Amanpreet Sethi and Deepak Chawla 32-49. Chapter 4: Mimics of Neonatal Sepsis. M. Girish and G. Subramaniam 50-66. Chapter 5: Diagnosis of Pulmonary Tuberculosis:. What Every Pediatrician Should Know!. Joseph L Mathew 67-88. Chapter 6: Evaluation of Children with Primary. Immunodeficiencies. M. Girish and G. Subramaniam 89-103. Chapter 7: Diabetic Ketoacidosis - Whats New?. Neha Agarwal and Anurag Bajpai 104-122. Chapter 8: Growth Hormone Therapy - State of the Art!. Chetankumar Dave and Anurag Bajpai 123-146. Chapter 9: Management of Arrhythmias in. Pediatric Emergency. Manojkumar Rohit and Ganesh Kasinadhuni ...
AT-100<...AT-100<...
AT-100 is a protein replacement therapy targeting Bronchopulmonary Dysplasia. AT-100 is a recombinant form of human surfactant protein-D (rhSP-D). SP-D performs 3 critical roles in maintaining healthy lung fuction.
Bronchopulmonary arterial shunting without anatomic anastomosis in the dog. | Circulation ResearchBronchopulmonary arterial shunting without anatomic anastomosis in the dog. | Circulation Research
The effects of bronchial arterial administration of vasoactive substances on the pulmonary circulation were studied by a new technique for selective catheterization of a bronchial artery in intact dogs. In most experiments, this technique permitted pressor agents to be distributed mainly to one lung with smaller amounts to the other lung. The intercostal arteries were avoided, and in all but 2 of 23 experiments only microscopic quantities of injected India ink could be identified in the distribution of the esophageal and mediastinal branches. These studies indicate that serotonin, angiotensin, histamine, and norepinephrine injected selectively into a bronchial artery increase lobar arterial pressure. Since blood flow was constant and left atrial pressure did not change, the increase in pressure suggests active pulmonary vasoconstriction. Additionally, the responses to bronchial and lobar arterial injections of pressor agents were similar. The contribution of bronchopulmonary shunt flow to ...
Anterior basal (bronchopulmonary) segment [S VIII] definition | Drugs.comAnterior basal (bronchopulmonary) segment [S VIII] definition | Drugs.com
Definition of anterior basal (bronchopulmonary) segment [S VIII]. Provided by Stedmans medical dictionary and Drugs.com. Includes medical terms and definitions.
Dysplasia - WikipediaDysplasia - Wikipedia
Some tests which detect cancer could be called "screening for epithelial dysplasia". The principle behind these tests is that physicians expect dysplasia to occur at the same rate in a typical individual as it would in many other people. Because of this, researchers design screening recommendations which assume that if a physician can find no dysplasia at certain time, then doing testing before waiting until new dysplasia could potentially develop would be a waste of medical resources for the patient and the healthcare provider because the chances of detecting anything is extremely low. Some examples of this in practice are that if a patient whose endoscopy did not detect dysplasia on biopsy during screening for Barretts esophagus, then research shows that there is little chance of any test detecting dysplasia for that patient within three years.[2][3][4]. Individuals at average-risk for colorectal cancer should have another screening after ten years if they get a normal result and after five ...
Krames Online - Chronic Lung Disease: Notes for Family and FriendsKrames Online - Chronic Lung Disease: Notes for Family and Friends
Being close to someone with chronic lung disease will likely mean some changes in your life. As your loved one copes with chronic lung disease, you may be asked to be a helper, caregiver, or source of support.
Living with Chronic Lung DiseaseLiving with Chronic Lung Disease
A loving relationship with your partner can help you deal with your chronic lung disease and the emotions that come with it. Yet a person with a chronic lung disease may have problems that interfere with being close.
Living with Chronic Lung DiseaseLiving with Chronic Lung Disease
A loving relationship with your partner can help you deal with your chronic lung disease and the emotions that come with it. Yet a person with a chronic lung disease may have problems that interfere with being close.
PNNL: From Omics Novel Glimpses into Early Lung DevelopmentPNNL: From Omics Novel Glimpses into Early Lung Development
The development of lungs and the process that enables respiration is still not well understood at the molecular level. To fill the knowledge gaps, PNNL scientists are systematically characterizing normal lung development in mice and humans.
Prospective study to evaluate the kind of prone position concerning nursing, pulmonary outcome and material and personnel...Prospective study to evaluate the kind of prone position concerning nursing, pulmonary outcome and material and personnel...
Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.. ...
Development of a novel genetic approach to study lung mesenchymal cell signaling - Wei ShiDevelopment of a novel genetic approach to study lung mesenchymal cell signaling - Wei Shi
Reciprocal interaction between lung mesenchymal and epithelial cells is essential for normal lung development and homeostasis. Therefore, alterations in lung me...
Search Articles | University of Toronto LibrariesSearch Articles | University of Toronto Libraries
This review summarizes our current knowledge on lung vasculogenesis and angiogenesis during normal lung development and the regulation of fetal and postnatal ...
Adventures in chronic lung disease in Africa - University of PlymouthAdventures in chronic lung disease in Africa - University of Plymouth
Whats on at Plymouth University: Adventures in chronic lung disease in Africa. What is the scale and what can we do about it? Plymouth University, 19 September 2017.
Oxygen toxicityOxygen toxicity
Infant respiratory distress syndromeInfant respiratory distress syndrome
Pulmonary hygienePulmonary hygiene
Prohibition of drugsProhibition of drugs
Neonatal intensive care unitNeonatal intensive care unit
Václav VojtaVáclav Vojta
CaffeineCaffeine
Pulmonary interstitial emphysemaPulmonary interstitial emphysema
Wilson-Mikity syndromeWilson-Mikity syndrome
AnalepticAnaleptic
Endothelial colony forming cellEndothelial colony forming cell
LysozymeLysozyme
Yoon Bo-hyunYoon Bo-hyun
氧气中毒 - 维基百科，自由的百科全书氧气中毒 - 维基百科，自由的百科全书
Chest radiographChest radiograph
Continuous positive airway pressureContinuous positive airway pressure
Chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease
Preterm birthPreterm birth
Exhaled nitric oxideExhaled nitric oxide
Bubble CPAPBubble CPAP
MycoplasmaMycoplasma
Oxygen toxicityOxygen toxicity
Chronic lung diseaseChronic lung disease
PalivizumabPalivizumab
LucinactantLucinactant
Neonatal intensive care unitNeonatal intensive care unit
George Siber bibliographyGeorge Siber bibliography
Henrik VerderHenrik Verder
PiclamilastPiclamilast
PlasmalogenPlasmalogen
Neonatal conjunctivitisNeonatal conjunctivitis
Chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease
Necrotizing enterocolitisNecrotizing enterocolitis
Erbs palsyErb's palsy
StillbirthStillbirth
Hemolytic disease of the newbornHemolytic disease of the newborn
Pleural diseasePleural disease
ಪಲ್ಮನರಿ ಎಂಬಾಲಿಸಮ್‌ (ಶ್ವಾಸಕೋಶದ ಧಮನಿಬಂಧ) - ವಿಕಿಪೀಡಿಯಪಲ್ಮನರಿ ಎಂಬಾಲಿಸಮ್‌ (ಶ್ವಾಸಕೋಶದ ಧಮನಿಬಂಧ) - ವಿಕಿಪೀಡಿಯ
Confined placental mosaicismConfined placental mosaicism
List of diseases (B)List of diseases (B)
Tüümus - VikipeediaTüümus - Vikipeedia
MycoplasmaMycoplasma
Prohibition of drugsProhibition of drugs
ढाँचा:Pediatric conditions originating in the perinatal period - विकिपिडियाढाँचा:Pediatric conditions originating in the perinatal period - विकिपिडिया
Bullous pemphigoidBullous pemphigoid
Continuous positive airway pressureContinuous positive airway pressure
Intraventricular hemorrhageIntraventricular hemorrhage
BPDBPD
AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesInformation ScienceNamed GroupsHealth CareGeographicals
Bronchopulmonary DysplasiaAspergillosis, Allergic BronchopulmonaryInfant, PrematureInfant, NewbornInfant, Very Low Birth WeightHyperoxiaInfant, Premature, DiseasesRespiratory Distress Syndrome, NewbornInfant, Extremely Low Birth WeightGestational AgeBronchopulmonary SequestrationLungUreaplasma InfectionsRespiration, ArtificialIntensive Care Units, NeonatalOxygen Inhalation TherapyFibrous Dysplasia of BoneInfant, Extremely PrematureUreaplasma urealyticumChorioamnionitisPulmonary SurfactantsRespiratory AspirationPulmonary AlveoliIntensive Care, NeonatalEctodermal DysplasiaPapioAnimals, NewbornLung InjuryBone Diseases, DevelopmentalUreaplasmaLung DiseasesLeukomalacia, PeriventricularInfant, Low Birth WeightDevelopmental DisabilitiesAmbroxolTracheaRetinopathy of PrematurityAspergillus fumigatusSucking BehaviorApneaConsensus Development Conferences, NIH as TopicDuctus Arteriosus, PatentApgar ScorePremature BirthHyaline Membrane DiseaseBirth WeightTransducers, PressureMaximal Expiratory Flow RatePregnancyFunctional Residual CapacityUterine Cervical DysplasiaDexamethasoneBronchial DiseasesFibromuscular DysplasiaPneumocytesGastrointestinal ContentsIntermittent Positive-Pressure VentilationContinuous Positive Airway PressureSuctionPsychomotor DisordersAdministration, InhalationBronchoalveolar Lavage FluidVentilator WeaningOsteochondrodysplasiasPortugalRetrospective StudiesFibrous Dysplasia, MonostoticDisease Models, AnimalFatty AlcoholsRespiratory Function TestsFibrous Dysplasia, PolyostoticFetusLung Diseases, FungalOxygenEnterocolitis, NecrotizingProspective StudiesHip Dysplasia, CanineBronchiectasisCleidocranial DysplasiaRetinal DysplasiaInfant, Newborn, DiseasesCerebral PalsyRisk FactorsFollow-Up StudiesBronchial NeoplasmsAdrenal Cortex HormonesHip Dislocation, Congenital
Bronchopulmonary Dysplasia (BPD)Bronchopulmonary Dysplasia (BPD)
Postnatal use of corticosteroids in bronchopulmonary dysplasiaPostnatal use of corticosteroids in bronchopulmonary dysplasia
Bronchopulmonary Dysplasia - NORD (National Organization for Rare Disorders)Bronchopulmonary Dysplasia - NORD (National Organization for Rare Disorders)
Bronchopulmonary Dysplasia Treatments | Boston Childrens HospitalBronchopulmonary Dysplasia Treatments | Boston Children's Hospital
Impact of a Physiologic Definition on Bronchopulmonary Dysplasia Rates | American Academy of PediatricsImpact of a Physiologic Definition on Bronchopulmonary Dysplasia Rates | American Academy of Pediatrics
Frontiers | Bronchopulmonary Dysplasia Early Changes Leading to Long-Term Consequences | MedicineFrontiers | Bronchopulmonary Dysplasia Early Changes Leading to Long-Term Consequences | Medicine
Bronchopulmonary Dysplasia - Five More Questions That You Should Ask Your DoctorBronchopulmonary Dysplasia - Five More Questions That You Should Ask Your Doctor
Genes Associated With Bronchopulmonary Dysplasia and Retinopathy of Prematurity - Full Text View - ClinicalTrials.govGenes Associated With Bronchopulmonary Dysplasia and Retinopathy of Prematurity - Full Text View - ClinicalTrials.gov
Bronchopulmonary Dysplasia Global Clinical Trials Review, H1, 2013 | Jul 23, 2013 - ReleaseWireBronchopulmonary Dysplasia Global Clinical Trials Review, H1, 2013 | Jul 23, 2013 - ReleaseWire
Adrenomedullin regulated by miRNA-574-3p protects premature infants with bronchopulmonary dysplasia | Bioscience Reports |...Adrenomedullin regulated by miRNA-574-3p protects premature infants with bronchopulmonary dysplasia | Bioscience Reports |...
Misdiagnosis of Underlying Causes of Bronchopulmonary dysplasia - RightDiagnosis.comMisdiagnosis of Underlying Causes of Bronchopulmonary dysplasia - RightDiagnosis.com
Long-Term Effects of Inhaled Budesonide for Bronchopulmonary Dysplasia - Zurich Open Repository and ArchiveLong-Term Effects of Inhaled Budesonide for Bronchopulmonary Dysplasia - Zurich Open Repository and Archive
RePub, Erasmus University Repository: Preeclampsia and risk of developing bronchopulmonary dysplasia in very preterm neonatesRePub, Erasmus University Repository: Preeclampsia and risk of developing bronchopulmonary dysplasia in very preterm neonates
MicroRNA-mRNA interactions in a murine model of hyperoxia-induced bronchopulmonary dysplasia | BMC Genomics | Full TextMicroRNA-mRNA interactions in a murine model of hyperoxia-induced bronchopulmonary dysplasia | BMC Genomics | Full Text
Bronchopulmonary dysplasiaBronchopulmonary dysplasia
Clinical Trial Evaluating the Effect of Prolact CR(R) on Length of Stay and Bronchopulmonary Dysplasia Among Very Low Birth...Clinical Trial Evaluating the Effect of Prolact CR(R) on Length of Stay and Bronchopulmonary Dysplasia Among Very Low Birth...
Bronchopulmonary dysplasia: MedlinePlus Medical EncyclopediaBronchopulmonary dysplasia: MedlinePlus Medical Encyclopedia
Bronchopulmonary dysplasia - WikipediaBronchopulmonary dysplasia - Wikipedia
Summary Proceedings From the Bronchopulmonary Dysplasia Group | PediatricsSummary Proceedings From the Bronchopulmonary Dysplasia Group | Pediatrics
Changing incidence of bronchopulmonary dysplasia. - PubMed - NCBIChanging incidence of bronchopulmonary dysplasia. - PubMed - NCBI
Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia. - PubMed - NCBIEarly inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia. - PubMed - NCBI
Bronchopulmonary Dysplasia | BPD | Symptoms, Diagnosis, TreatmentBronchopulmonary Dysplasia | BPD | Symptoms, Diagnosis, Treatment
Search of: Bronchopulmonary Dysplasia | Antibodies - Modify Search - ClinicalTrials.govSearch of: 'Bronchopulmonary Dysplasia' | 'Antibodies' - Modify Search - ClinicalTrials.gov
Bronchopulmonary Dysplasia (BPD): Symptoms, Diagnosis and TreatmentBronchopulmonary Dysplasia (BPD): Symptoms, Diagnosis and Treatment
Bronchopulmonary Dysplasia | Boston Childrens HospitalBronchopulmonary Dysplasia | Boston Children's Hospital
Current Pharmacologic Approaches for Prevention and Treatment of Bronchopulmonary DysplasiaCurrent Pharmacologic Approaches for Prevention and Treatment of Bronchopulmonary Dysplasia
Bronchopulmonary Dysplasia | Respiratory Insufficiency - Causes, Clinical features, ManagementBronchopulmonary Dysplasia | Respiratory Insufficiency - Causes, Clinical features, Management
Morphometric analysis of the lung in bronchopulmonary dysplasiaMorphometric analysis of the lung in bronchopulmonary dysplasia
Bronchopulmonary dysplasia: new becomes old again!Bronchopulmonary dysplasia: new becomes old again!
Bronchopulmonary Dysplasia | American Lung AssociationBronchopulmonary Dysplasia | American Lung Association
Frontiers | Biomarkers for Bronchopulmonary Dysplasia in the Preterm Infant | PediatricsFrontiers | Biomarkers for Bronchopulmonary Dysplasia in the Preterm Infant | Pediatrics
Bronchopulmonary Dysplasia | Springer for Research & DevelopmentBronchopulmonary Dysplasia | Springer for Research & Development
Bronchopulmonary Dysplasia - Lahey HealthBronchopulmonary Dysplasia - Lahey Health
Thioredoxin Reductase-1 Inhibition Augments Endogenous Glutathione-Dependent Antioxidant Responses in Experimental...Thioredoxin Reductase-1 Inhibition Augments Endogenous Glutathione-Dependent Antioxidant Responses in Experimental...
Bronchopulmonary dysplasia | Archives of Disease in ChildhoodBronchopulmonary dysplasia | Archives of Disease in Childhood
Diagnosing and Treating Bronchopulmonary Dysplasia | American Lung AssociationDiagnosing and Treating Bronchopulmonary Dysplasia | American Lung Association
Pentoxifylline for the prevention of bronchopulmonary dysplasia in preterm infants | CochranePentoxifylline for the prevention of bronchopulmonary dysplasia in preterm infants | Cochrane
Bronchopulmonary Dysplasia | ADC Fetal & Neonatal EditionBronchopulmonary Dysplasia | ADC Fetal & Neonatal Edition
AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesInformation ScienceNamed GroupsHealth CareGeographicals
Bronchopulmonary DysplasiaAspergillosis, Allergic BronchopulmonaryInfant, PrematureInfant, NewbornInfant, Very Low Birth WeightHyperoxiaInfant, Premature, DiseasesRespiratory Distress Syndrome, NewbornInfant, Extremely Low Birth WeightGestational AgeBronchopulmonary SequestrationLungUreaplasma InfectionsRespiration, ArtificialIntensive Care Units, NeonatalOxygen Inhalation TherapyFibrous Dysplasia of BoneInfant, Extremely PrematureUreaplasma urealyticumChorioamnionitisPulmonary SurfactantsRespiratory AspirationPulmonary AlveoliIntensive Care, NeonatalEctodermal DysplasiaPapioAnimals, NewbornLung InjuryBone Diseases, DevelopmentalUreaplasmaLung DiseasesLeukomalacia, PeriventricularInfant, Low Birth WeightDevelopmental DisabilitiesAmbroxolTracheaRetinopathy of PrematurityAspergillus fumigatusSucking BehaviorApneaConsensus Development Conferences, NIH as TopicDuctus Arteriosus, PatentApgar ScorePremature BirthHyaline Membrane DiseaseBirth WeightTransducers, PressureMaximal Expiratory Flow RatePregnancyFunctional Residual CapacityUterine Cervical DysplasiaDexamethasoneBronchial DiseasesFibromuscular DysplasiaPneumocytesGastrointestinal ContentsIntermittent Positive-Pressure VentilationContinuous Positive Airway PressureSuctionPsychomotor DisordersAdministration, InhalationBronchoalveolar Lavage FluidVentilator WeaningOsteochondrodysplasiasPortugalRetrospective StudiesFibrous Dysplasia, MonostoticDisease Models, AnimalFatty AlcoholsRespiratory Function TestsFibrous Dysplasia, PolyostoticFetusLung Diseases, FungalOxygenEnterocolitis, NecrotizingProspective StudiesHip Dysplasia, CanineBronchiectasisCleidocranial DysplasiaRetinal DysplasiaInfant, Newborn, DiseasesCerebral PalsyRisk FactorsFollow-Up StudiesBronchial NeoplasmsAdrenal Cortex HormonesHip Dislocation, Congenital
Lung diseasePretermSeverePrematurityIncidenceAbstractCorticosteroidsMortalityPathogenesisNeonatologyGestational ageSTEROIDSChronic respiratory diseaseComplicationPrevention or treatmentAngiogenesisPrevent bronchopulmonary dysplasiaBiomarkersClinicalPreterm birthKnown as bronchopulmonary dysplasiaPrediction of Bronchopulmonary DysplasiaManagement of bronchopulmonary dysplasiaDevelopment Of Bronchopulmonary DysplasiaPremature babiesNeonatesTreat bronchopulmonary dysplasiaDevelop bronchopulmonary dysplasiaTreating Bronchopulmonary DysplasiaOutcomesInfants with and without bronchopulmonarySymptoms of BronchopulmonaryTreatment of bronchopulmonaryPrevention of bronchopulmonaryPathogenesis of bronchopulmonaryEpidemiologyPulmonary HypertensionDiagnosisMechanical ventilationRisk FactorsOutcomeDefinitionNewbornPostnatalPathologyAbman SH
Lung disease8
Preterm4
Severe3
  • CONCLUSION: Both bronchopulmonary dysplasia and perinatal clinical data accurately identify ELGANs at risk for persistent and severe respiratory morbidity at 1 year. (duke.edu)
  • Bronchopulmonary dysplasia (BPD), defined as oxygen dependence at 36 weeks of postmenstrual age (PMA), is a severe complications of extremely premature infants. (biomedcentral.com)
  • Newswise - CINCINNATI- Researchers suggest a possible cell-based therapy to stimulate lung development in fragile premature infants who suffer from a rare condition called Bronchopulmonary Dysplasia (BPD), which in the most severe cases can lead to lifelong breathing problems and even death. (newswise.com)
Prematurity1
Incidence1
  • Postnatal corticosteroid administration is an area of intense clinical interest because of the desire to reduce the incidence and severity of bronchopulmonary dysplasia (BPD) ( table 1 ). (uptodate.com)
Abstract1
  • abstract = "Pulmonary and renal responses to furosemide were evaluated in ten infants with stage III-IV bronchopulmonary dysplasia. (elsevier.com)
Corticosteroids2
Mortality1
Pathogenesis2
Neonatology1
  • Bronchopulmonary dysplasia (BPD) is the endpoint of many intervention trials in neonatology, yet the outcome measure when based solely on oxygen administration may be confounded by differing criteria for oxygen administration between physicians. (aappublications.org)
Gestational age1
  • Bronchopulmonary Dysplasia and Perinatal Characteristics Predict 1-Year Respiratory Outcomes in Newborns Born at Extremely Low Gestational Age: A Prospective Cohort Study. (duke.edu)
STEROIDS1
  • Are inhaled steroids safe and effective for prevention or treatment of bronchopulmonary dysplasia? (readbyqxmd.com)
Chronic respiratory disease1
Complication1
  • This study has demonstrated that furosemide administration has only a short-term effect in the lung but has a potential for long-term complication on electrolytes and calcium balance in infants with well-established stage III-IV bronchopulmonary dysplasia. (elsevier.com)
Prevention or treatment1
  • Two meta-analyses have divided these trials based upon the timing of administration and their focus on either prevention or treatment of established bronchopulmonary dysplasia (BPD) [ 1,2 ]. (uptodate.com)
Angiogenesis1
  • In bronchopulmonary dysplasia (BPD), disrupted angiogenesis may result from an imbalance between pro- and anti-angiogenic factors triggered by inflammation, leading to the late development of pulmonary artery hypertension (PAH). (figshare.com)
Prevent bronchopulmonary dysplasia5
Biomarkers1
Clinical12
Preterm birth4
Known as bronchopulmonary dysplasia1
Prediction of Bronchopulmonary Dysplasia1
  • describing the prediction of bronchopulmonary dysplasia (BPD) development at 1 week of age. (bmj.com)
Management of bronchopulmonary dysplasia3
Development Of Bronchopulmonary Dysplasia2
Premature babies3
Neonates2
Treat bronchopulmonary dysplasia2
  • The report offers an exhaustive analysis of the pipeline molecules under investigation within the defined data collection period to treat bronchopulmonary dysplasia. (apnews.com)
  • Policy statement-postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia. (aafp.org)
Develop bronchopulmonary dysplasia2
  • Background: One-third to one-half of all infants born before the 28th week of gestation develop bronchopulmonary dysplasia (BPD). (harvard.edu)
  • An exaggerated inflammatory response occurs in the first few days of life in infants who subsequently develop bronchopulmonary dysplasia (BPD). (biomedcentral.com)
Treating Bronchopulmonary Dysplasia1
  • Hartert, Tina V. / Update on Vitamin E and Its Potential Role in Preventing or Treating Bronchopulmonary Dysplasia . (northwestern.edu)
Outcomes4
Infants with and without bronchopulmonary2
  • An Echocardiographic Screening Program Helps to Identify Pulmonary Hypertension in Extremely Low Birthweight Infants with and without Bronchopulmonary Dysplasia: A Single-Center Experience. (semanticscholar.org)
  • In this study, we aimed to analyze differences in plasma protein abundances between infants with and without bronchopulmonary dysplasia (BPD), to add new insights into a better understanding of the pathogenesis of this disease. (springermedizin.de)
Symptoms of Bronchopulmonary2
Treatment of bronchopulmonary5
Prevention of bronchopulmonary2
Pathogenesis of bronchopulmonary3
Epidemiology1
Pulmonary Hypertension5
Diagnosis2
Mechanical ventilation2
Risk Factors2
Outcome3
Definition1
Newborn1
  • Bronchopulmonary dysplasia (BPD) is a long-term ( chronic ) lung condition that affects newborn babies who were either put on a breathing machine after birth or were born very early (prematurely). (medlineplus.gov)
Postnatal1
  • Because of these issues, the postnatal use of either systemic or inhaled corticosteroids in bronchopulmonary dysplasia is a controversial and continuously evolving subject. (uptodate.com)
Pathology1
  • Husain AN, Siddiqui NH, Stocker JT (1998) Pathology of arrested acinar development in postsurfactant bronchopulmonary dysplasia. (springer.com)
Abman SH1
  • McEvoy C, Jain L, Schmidt B, Abman SH, Bancalari E, Aschner J. Bronchopulmonary dysplasia: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. (springer.com)